NZ619872B2

NZ619872B2 - Microbial oil compositions containing omega-3 polyunsaturated fatty acids and dosage forms containing such oils.

Info

Publication number: NZ619872B2
Application number: NZ619872A
Authority: NZ
Inventors: Kirk E Apt; Paul Warren Behrens; Jon Milton Hansen; Iii Joseph W Pfeifer; Tracey Lynn Stahl; Ross Zirkle
Original assignee: Dsm Ip Assets Bv
Priority date: 2011-07-21
Filing date: 2012-07-20
Publication date: 2016-11-01

Abstract

Provided are microbial oils containing omega-3 polyunsaturated fatty acids, wherein the omega-3 polyunsaturated fatty acids comprise greater than or equal to 90% by weight docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). Further provided are dosage forms containing such oils.

Description

MICROBIAL OIL COMPOSITIONS CONTAINING OMEGA-3 POLYUNSATURATED FATTY ACIDS AND DOSAGE FORMS CONTAINING SUCH OILS.

The content of the electronically submitted sequence listing ("sequence listing.txt", 5,136 bytes, created on July 20, 2011) filed with the application is incorporated herein by reference in its entirety.

The present invention is directed to isolated rganisms as well as strains and mutants thereof, biomasses, microbial oils, compositions, and cultures; methods of producing the microbial oils, biomasses, and mutants; and s of using the isolated microorganisms, biomasses, and ial oils.

Fatty acids are classified based on the length and saturation characteristics of the carbon chain. Fatty acids are termed short chain, medium chain, or long chain fatty acids based on the number of carbons present in the chain, are termed saturated fatty acids when no double bonds are present between the carbon atoms, and are termed unsaturated fatty acids when double bonds are present. Unsaturated long chain fatty acids are monounsaturated when only one double bond is present and are polyunsaturated when more than one double bond is present.

Polyunsaturated fatty acids (PUFAs) are classified based on the position of the first double bond from the methyl end of the fatty acid: 3 (n-3) fatty acids n a first double bond at the third carbon, while omega-6 (n-6) fatty acids contain a first double bond at the sixth carbon. For example, docosahexaenoic acid ("DHA") is an omega-3 long chain polyunsaturated fatty acid FA) with a chain length of 22 carbons and 6 double bonds, often designated as "22:6 n-3." Other 3 LC-PUFAs include eicosapentaenoic acid ("EPA"), designated as "20:5 n-3," and omega-3 docosapentaenoic acid ("DPA n-3"), designated as "22:5 n-3." DHA and EPA have been termed "essential" fatty acids. Omega-6 LC-PUFAs include arachidonic acid ), designated as "20:4 n-6," and omega-6 docosapentaenoic acid ("DPA n-6"), designated as "22:5 n-6." Omega-3 fatty acids are biologically important les that affect cellular physiology due to their presence in cell membranes, regulate tion and gene expression of biologically active compounds, and serve as biosynthetic substrates.

Roche, H. M., Proc. Nutr. Soc. 58: 397 -401 (1999). DHA, for example, accounts for approximately 15%-20% of lipids in the human cerebral , 30%-60% of lipids in the retina, is concentrated in the testes and sperm, and is an ant component of breast milk. Bergé, J.P., and Barnathan, G.. Adv. Biochem. Eng. Biotechnol. 96:49-125 (2005).

DHA accounts for up to 97% of the omega-3 fatty acids in the brain and up to 93% of the omega-3 fatty acids in the retina. Moreover, DHA is essential for both fetal and infant development as well as maintenance of cognitive functions in adults. Id. Because omega-3 fatty acids are not synthesized de novo in the human body, these fatty acids must be derived from ional sources.

Flaxseed oil and fish oils are considered good dietary sources of omega-3 fatty acids. Flaxseed oil contains no EPA, DHA, DPA, or ARA but rather contains linolenic acid (C18:3 n-3), a building block enabling the body to cture EPA. There is evidence, however, that the rate of lic conversion can be slow and variable, particularly among those with impaired health. Fish oils vary considerably in the type and level of fatty acid composition depending on the particular species and their diets.

For example, fish raised by aquaculture tend to have a lower level of omega-3 fatty acids than those in the wild. Furthermore, fish oils carry the risk of containing environmental contaminants and can be associated with stability problems and a fishy odor or taste.

Thraustochytrids are microorganisms of the order Thraustochytriales.

Thraustochytrids include members of the genus Schizochytrium and Thraustochytrium and have been recognized as an alternative source of omega-3 fatty acids, including DHA and EPA. See U.S. Patent No. 5,130,242. Oils produced from these marine heterotrophic microorganisms often have simpler polyunsaturated fatty acid es than corresponding fish or microalgal oils. Lewis, T.E., Mar. Biotechnol. 1: 580 -587 (1999). Strains of thraustochytrid species have been reported to produce omega-3 fatty acids as a high percentage of the total fatty acids produced by the sms. U.S. Patent No. 5,130,242; Huang, J. et al., J. Am. Oil. Chem. Soc. 78: 605 -610 (2001); Huang, J. et al., Mar.

Biotechnol. 5: 450 -457 . However, isolated thraustochytrids vary in the identity and s of LC-PUFAs ed, such that some previously described strains can have undesirable levels of omega-6 fatty acids and/or can demonstrate low productivity in culture. As such, a continuing need exists for the ion of microorganisms demonstrating high productivity and ble LC-PUFA profiles. [0007a] The discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purpose of ing a context for the present - 2a - invention. It is not suggested or ented that any or all of these matters formed part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application. [0007b] Where the terms "comprise", "comprises", ised" or "comprising" are used in this specification (including the claims) they are to be interpreted as specifying the presence of the stated features, integers, steps or components, but not precluding the presence of one or more other features, integers, steps or components, or group f.

The present invention is directed to an isolated microorganism of the s deposited under ATCC Accession No. PTA-10212.

The present invention is directed to an isolated microorganism having the characteristics of the species deposited under ATCC Accession No. PTA-10212.

The present invention is directed to an isolated microorganism comprising an 18s rRNA comprising a polynucleotide sequence of SEQ ID NO:1 or a polynucleotide sequence having at least 94% identity to SEQ ID NO:1.

The present invention is directed to an isolated microorganism comprising an 18S rRNA cleotide sequence that has at least 94% identity to an 18S rRNA polynucleotide sequence of the rganism deposited under ATCC Accession No.

PTA-10212.

The present invention is directed to an isolated microorganism of the species deposited under ATCC Accession No. PTA-10208, wherein the total fatty acids produced by the microorganism comprises more than about 10% by weight eicosapentaenoic acid.

The present invention is directed to an isolated microorganism having the teristics of the species-deposited under ATCC Accession No. PTA-10208, wherein the total fatty acids produced by the rganism comprises more than about 10% by weight pentaenoic acid.

The present invention is directed to an isolated microorganism that produces a triacylglycerol fraction, wherein pentaenoic acid content of the triacylglycerol fraction is at least about 12% by weight.

In some embodiments, the isolated microorganism of the invention is a mutant strain.

The present invention is directed to an isolated microorganism deposited under ATCC Accession No. 212, PTA-10213, 214, PTA-10215, PTA-10208, PTA-10209, PTA-10210, or PTA-10211.

The t invention is directed to a biomass comprising any of the microorganisms of the ion or mixtures thereof.

The present invention is directed to an isolated biomass, wherein at least about % by weight of a dry cell weight of the biomass are fatty acids, n more than about 10% by weight of fatty acids is eicosapentaenoic acid, and wherein the fatty acids comprise less than about 5% by weight each of donic acid and docosapentaenoic acid n-6. In some embodiments, at least about 25% by weight of the fatty acids is docosahexaenoic acid.

In some embodiments, the present invention is directed to an isolated biomass comprising triacylglycerol, wherein at least about 12% by weight of triacylglycerol is eicosapentaenoic acid.

In some embodiments, the present invention is ed to any of the isolated biomasses of the invention wherein the fatty acids further comprise less than about 5% by weight each of oleic acid, linoleic acid, nic acid, eicosenoic acid, and erucic acid.

The present invention is directed to an isolated culture comprising any of the rganisms of the invention or mixtures f.

The present invention is directed to a food product, cosmetic, or pharmaceutical composition for a non-human animal or human, comprising any of the microorganisms or biomasses of the invention or es thereof.

The present invention is directed to a microbial oil comprising at least about 20% by weight eicosapentaenoic acid and less than about 5% by weight each of arachidonic acid, docosapentaenoic acid n-6, oleic acid, linoleic acid, linolenic acid, eicosenoic acid, erucic acid, and stearidonic acid. In some embodiments, the microbial oil r comprises at least about 25% by weight docosahexaenoic acid.

The t invention is directed to a microbial oil comprising a triacylglycerol on of at least about 10% by weight, wherein at least about 12% by weight of the fatty acids in the triacylglycerol fraction is eicosapentaenoic acid, wherein at least about % by weight of the fatty acids in the triacylglycerol fraction is docosahexaenoic acid, and wherein less than about 5% by weight of the fatty acids in the triacylglycerol fraction is arachidonic acid. [0024a] The present invention is directed to a refined microbial oil comprising omega-3 saturated fatty acids comprising docosahexaenoic acid and eicosapentaenoic acid in an amount of ≥90%, by weight, of the total amount of omega-3 saturated fatty acids, n the amount of eicosapentaenoic acid, by weight, is from 29% to 55% of the total amount of docosahexaenoic acid and eicosapentaenoic acid, and the amount of docosahexaenoic acid, by weight, is from 45% to 71% of the total amount of docosahexaenoic acid and eicosapentaenoic acid. [0024b] The present invention is directed to a refined microbial oil comprising omega-3 polyunsaturated fatty acids sing docosahexaenoic acid and eicosapentaenoic acid - 4a - in an amount of ≥90%, by weight, of the total amount of omega-3 polyunsaturated fatty acids; and docosapentaenoic acid in an amount of from 0% to 2%, by , of the total amount of omega-3 polyunsaturated fatty acids, wherein the amount of eicosapentaenoic acid, by weight, is from 10% to 25% of the total amount of docosahexaenoic acid and eicosapentaenoic acid, the amount of docosahexaenoic acid, by weight, is from 75% to 90% of the total amount of docosahexaenoic acid and eicosapentaenoic acid.

The present invention is directed to a food product, cosmetic, or pharmaceutical composition for a non-human animal or human, comprising any of the microbial oils of the invention. In some embodiments, the food product is an infant formula. In some ments, the infant formula is suitable for premature infants. In some ments, the food product is a milk, a beverage, a therapeutic drink, a nutritional drink, or a combination thereof. In some embodiments, the food product is an additive for the nonhuman animal or human food. In some embodiments, the food product is a nutritional supplement. In some ments, the food product is an animal feed. In some embodiments, the animal feed is an aquaculture feed. In some embodiments, the animal feed is a domestic animal feed, a zoological animal feed, a work animal feed, a livestock feed, or a combination thereof.

The present invention is directed to a method for producing a ial oil comprising omega-3 fatty acids, the method comprising: growing any of the isolated microorganisms of the invention or mixtures thereof in a culture to produce an oil comprising 3 fatty acids. In some embodiments, the method further comprises extracting the oil.

The t ion is directed to a method for producing a microbial oil sing 3 fattyacids, the method comprising extracting an oil comprising omega-3 fatty acids from any of the biomasses of the invention. In some embodiments, the microbial oil is extracted using an organic solvent extraction process, for example hexane extraction. In some embodiments, the microbial oil is extracted using a solventless extraction s.

The present invention is directed to a microbial oil produced by a method. of the invention.

The present invention is ed to a method for producing a biomass of the invention, comprising: growing any of the isolated microorganisms of the invention or mixtures thereof in a culture to produce a s.

The present ion is directed to a biomass produced by a method of the invention.

The present invention is directed to a method for producing a mutant strain of the . invention, comprising: mutagenizing any of the microorganisms of the invention, and isolating the mutant strain.

The t invention is directed to use of any of the isolated microorganisms, biomasses, or microbial oils of the invention, or es thereof, for the manufacture of a ment for treatment of inﬂammation or a condition related thereto.

The present invention is directed to use of any of the isolated microorganisms, biomasses, or ial oils of the invention, or mixtures thereof, for treatment of inﬂammation or a condition related thereto.

The present invention is directed to any of the isolated microorganisms, biomasses, or microbial oilsof the invention, or mixtures thereof, for use in treatment of inﬂammation or a condition related thereto.

The present invention is directed to a method for treating ation or a condition related thereto in a subject in need thereof, comprising administering to the subject any of the isolated microorganisms, biomasses, or ial oils of the invention, or mixtures thereof, and a pharmaceutically acceptable r.

The present invention is directed to isolated microorganisms, as well as strains and mutants thereof, as well as biomasses, microbial oils, compositions, and cultures thereof. The present invention is directed to s of producing microbial oils, biomasses, and mutants from the microorganisms of the invention, and methods of using the microorganisms, biomasses, and microbial oils. The microorganisms described herein in part by high are highly productive and produce unique fatty acid proﬁles, characterized levels of omega-3 fatty acids, in particular high levels of EPA.

The invention is directed to isolated microorganisms and strains d therefrom. A strain that is "derived" from an isolated microorganism of the invention can be a natural or artiﬁcial derivative such as, fOr example, a mutant, variant, or recombinant strain. The term "isolated" as used herein does not necessarily reﬂect the extent to which a native form or an isolate has been purified, but indicates isolation or tion from native environment. An isolate can include, but is not limited to, an ed microorganism, an isolated biomass, an isolated culture, an isolated microbial oil, and an isolated sequence (such as an isolated cleotide sequence disclosed ). The "microorganism" as used herein includes, but is not limited to, the terms term "microalgae," stochytrid," and taxonomic classiﬁcations associated with any of the ted microorganisms described herein. The terms stochytriales," "thraustochytrid," "Schizochytrium," and "Thraustochytrium" as used in reference to any of the microorganisms of the invention, including the deposited microorganisms described , are based on present taxonomic classiﬁcations including available phylogenetic information and are not intended to be ’limiting in the event that the taxonomic classiﬁcations are revised after the ﬁling date of the present application.

In some embodiments, the invention is directed to an isolated rganism of the species deposited under ATCC Accession No. PTA-10212. The isolated microorganism associated with ATCC Accession No. PTA-10212 is also known herein as Thraustochytrium 5p. ATCC PTA-10212. The isolated rganism associated with ATCC ion No. PTA-10212 was deposited under the Budapest Treaty on July 14, 2009 at the American Type Culture Collection, Patent Depository, 10801 University Boulevard, Manassas, VA 20110-2209. In some embodiments, the invention is directed to an isolated strain deposited under ATCC Accession No. PTA-10212.

In some embodiments, the invention is directed to an ed microorganism having the characteristics of the species deposited under ATCC Accession No. PTA- 10212 or a strain derived therefrom. The characteristics of the species deposited under ATCC Accession No. PTA-10212 can include its growth and phenotypic properties (examples of phenotypic properties e morphological and uctive ties), its physical and chemical properties (such as dry weights and lipid proﬁles), its gene sequences, and combinations thereof, in which the characteristics distinguish the species over previously identiﬁed s. In some embodiments, the invention is directed to an isolated rganism having the characteristics of the species deposited under ATCC Accession No. PTA-10212, wherein the characteristics include an 185 rRNA comprising the polynucleotide sequence of SEQ ID NO:1 or a polynucleotide sequence having at least 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:1, the morphological and reproductive properties of the Species deposited under ATCC Accession No. PTA- 10212, and the fatty acid proﬁles of the species deposited under ATCC Accession No.

PTA-10212. In some embodiments, isolated microorganisms of the invention have phenotypic properties substantially identical to those of the microorganism deposited under ATCC Accession No. PTA-10212. In some embodiments, isolated microorganisms of the invention have growth properties substantially identical to those of the microorganism deposited under ATCC Accession No. 212. In some embodiments, the invention is directed to an isolated microorganism comprising an 185 rRNA sing the cleotide sequence of SEQ ID NO:l or a polynucleotide NO:1. sequence having at least 94%, 95%, 96%, 97%, 98%, or 99% ty to SEQ ID In some embodiments, the inventionis directed to an ed microorganism comprising an 185 rRNA polynucleotide ce that has at least 94% identity to the 18s rRNA polynucleotide sequence of the microorganism deposited under ATCC Accession No.

PTA-10212.

In some embodiments, the invention is directed to a mutant strain of the microorganism deposited under ATCC Accession No. PTA-10212. In r embodiments, the mutant strain is a strain deposited under ATCC Accession No. PTA- 10213, PTA-10214, or PTA-10215. The microorganisms associated with ATCC Accession Nos.rPTA-10213, PTA-10214, and 215 were deposited under the Budapest Treaty on July '14, 2009 at the American Type Culture Collection, Patent Depository, 10801 University Boulevard, Manassas, VA 20110-2209.

In some embodiments, the invention is directed to an isolated microorganism of the species deposited under ATCC Accession No. PTA-10208. The isolated microorganism ated with ATCC Accession No. PTA-10208 is also known herein as Schizochytrium PTA-10208. The microorganism associated with ATCC sp. ATCC Accession No. PTA-10208 was deposited under the Budapest Treaty on July 14, 2009 at the American Type e tion, Patent tory, 10801 University Boulevard, Manassas, VA 20110-2209. In some embodiments, the invention is directed to an isolated strain deposited under ATCC Accession No. PTA-10208.

In some embodiments, the invention is directed to an isolated microorganism of the species deposited under ATCC Accession No. PTA-10208, wherein the total fatty acids produced by the microorganism comprises more than about 10%, more than about 1 1%, more than about 12%, more than about 13%, more than about 14%, more than about. %, more than about 16%, more than about 17%, more than about 18%, more than about 19%, or more than about 20% by weight EPA. In some embodiments, the invention is directed to an ed microorganism of the species deposited under ATCC Accession No. PTA-10208, n the total fatty acids produced by the microorganism ses about 10% to about 55%, about 10% to about 50%, about 10% to about 45%, about 10% to about 40%, about 10% to about 35%, about 10% to about 30%, about 15% to about 55%, about 15% to about 50%, about 15% to about 45%, about 15% to about 40%, about % to about 35%, about 15% to about 30%, about 20% to about 55%, about 20% to about 50%, about 20% to about 45%, about 20% to about 40%, about 20% to about 35%, or about 20% to about 30% by weight EPA.

In some embodiments, the inVention is directed-to an isolated microorganism having the characteristics of the species deposited under ATCC Accession No. PTA- 10208, wherein the total fatty acids ed by the microorganism comprises more than about 10% by weight eicosapentaenoic acid. The characteristics of the microorganism deposited under ATCC ion No. PTA-10208 include its growth and phenotypic properties (examples of phenotypic properties include morphological and reproductive, properties), its physical and chemical properties (such as dry weights and lipid proﬁles), its gene sequences, and combinations thereof, in which the teristics distinguish the species is over previously identiﬁed s. In some embodiments, the invention directed to an isolated microorganism having the characteristics of the species deposited under ATCC Accession No. PTA-10212, wherein the characteristics include an 185 rRNA comprising the polynucleotide sequence of SEQ ID NO:2, the morphological and reproductive properties of the species deposited under ATCC Accession No. PTA-10208, and the fatty acid proﬁles of the species deposited under ATCC Accession No. PTA- 10208. In some embodiments, isolated microorganisms of the invention have al and al properties substantially identical to those of the microorganism deposited under ATCC Accession No. PTA-10208.

In of some embodiments, the invention is directed to a mutant strain the microorganism deposited under ATCC ion No. PTA-10208. In further ments, the mutant strain is a strain deposited under ATCC Accession No. PTA- 10209, PTA-10210, or PTA-10211. The microorganisms associated with ATCC Accession Nos. PTA-10209,.PTA-10210, and PTA-10211 were deposited under the Budapest Treaty on September 25, 2009 at the American Type Culture Collection, Patent Depository, 10801 University Boulevard, as, VA 20110-2209.

In some embodiments, the invention is directed to an isolated microorganism of the invention that es a triacylglycerol fraction, wherein the EPA content of the lglycerol fraction is atleast about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 16%, at .least about 17%, at least about 18%, at least about 19%, or at least about 20% by weight. In some embodiments, the invention is directed to an isolated microorganism that es a lglycerol fraction, wherein the EPA content of the triacylglycerol on is about 12% to abOut 55%, about 12 % to about 50%, about 12% to about 45%, about 12% to about 40%, about 12% to about 35%, about 12% to about 30%, about 15% to about 45%, about 15% to about 40%, about 15% to about 35%, about 15% to about 30%, or about 20% to about 30% by weight.

In some embodiments, the invention is directed to a mutant, variant, or recombinant of an isolated microorganism of the invention that produces a triacylglycerol fraction, wherein the EPA content of the triacylglycerol fraction is at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about %, at least about 16%, at least about 17%, at least about 18%, at least about 19%, or at least about 20% by weight. In some embodiments, the invention is directed to a mutant, t, or recombinant of an isolated microorganism of the invention that produces a triacylglycerol fraction, wherein the EPA content of the triacylglycerol fraction is about 12% to about 55%, about 12% to about 50%, about 12% to about 45%, about 12% to about 40%, about 12% to about 35%, about 12% to about 30%, about 15% to about 55%, about 15% to about 50%, about 15% to about 45%, about 15% to about 40%, about 15% to about to about 35%, about 15% to about 30%, about 20% to about 55%, about 20% 50%, about 20% to about 45%, about 20% to about 40%, about 20% to about 35%, or about 20% to about 30% by . Mutant strains can be produced by well-known procedures. Common procedures include irradiation, treatment at high temperatures, and treatment with a mutagen. Variant s can be other naturally occurring isolates and/or sub-isolates of the species described herein. Recombinant strains can be produced by any well-known methods in lar biology for the expression of exogenous genes or alteration of endogenous gene function or expression. In some embodiments, the mutant, variant, or recombinant strain produces a higher amount of omega-3 fatty acids, particularly EPA, than the wild—type strain. In some ments, the mutant, variant, or recombinant strain produces a lower amount of one or more fatty acids, such as lower amounts of DHA, ARA, DPA n-6, or combinations thereof. In some embodiments, the liter of culture mutant, variant, or recombinant strain produces a larger dry cell weight per than the wild-type strain. Such , variant, or recombinant strains are examples of s d from an isolated microorganism of the invention.

In some ments, an isolated microorganism of the invention, including in one or more mutants, variants, and recombinants thereof, comprises a fatty acid proﬁle fractions isolated from the microorganism. The one or more ons isolated from the microorganism include the total fatty acid fraction, the sterol esters fraction, the lglycerol fraction, the free fatty acid fraction, the sterol fraction, the diacylglycerol on, the polar fraction (including the phospholipid fraction), and combinations thereof. The fatty acid proﬁle for a speciﬁc fraction can include any of the fatty acid proﬁles associated with the speciﬁc fraction as sed herein.

The invention is directed to a method of producing a mutant comprising mutagenizing any of the microorganisms of the invention and isolating the mutant strain.

The invention is directed to a culture comprising one or more isolated microorganisms of the invention. Various fermentation ters for inoculating, growing, and ring ora, such as microalgae and thraustochytrids, are known in the art. See, reference herein in its e.g., US. Patent No. 5,130,242, incorporated by entirety. Liquid or solid media can contain natural or artiﬁcial sea water. Carbon s for heterotrophic growth include, but are not limited to, glucose, fructose, xylose, saccharose, maltose, soluble , es, ‘fucose, glucosamine, dextran, fats, oils, glycerol, sodium acetate, and mannitol. Nitrogen sources include, but are not limited to, peptone, yeast extract, polypeptone, malt extract, meat extract, casamino acid, corn steep liquor, organic nitrogen sources, sodium glutamate, urea, inorganic nitrogen sources, ammonium acetate, ammonium sulfate, ammonium de, and ammonium nitrate.

A typical media for growth of the microorganism deposited under ATCC Accession No. 212 is shown in Table 1: Table 1: PTA-10212 Vessel Media Ingredient concentration ranges Na2804 g/L 31.0 0-50, 15-45, or 25-35 NaCl g/L 0.625 0-25, 0.1~10, or 0.5-5' KCl g/L 1.0 0-5, 0.25-3, or 0.5-2 MgSO4'7HzO g/L 5.0 0-10, 2-8, or 3—6 (NH4)2SO4 g/L 0.44 0-10, 0.25-5, or 0.05-3 MSG'1H20 g/L 6.0 0-10, 4-8, or 5-7 CaClz g/L 0.29 0.1-5, 0.15-3, or 02-] T 154 (yeast extract) g/L 6.0 0-20, 01-10, or 1-7 KH2P04 g/L 0.8 01-10, 0.5-5, or 0.6-1.8 Post autoclave {Metalsi Citric acid mg/L 3.5 01-5000, 10-3000, or 3-2500 FeSO4'7H20 mg/L 10.30 0.1-100, 1-50, or 5-25 MnCl2'4H20 mg/L 3.10 0.1-100, 1-50, or 2-25 7H20 mg/L 3.10 0.01-100, 1-50, or 2-25 6H20 mg/L 0.04 '0-1, 0001-0. 1 , or 0.01-0.1 NazMoO4'2H20 mg/L 0.04 0.001.-1, 0005-05, or 0.01-0.l CuSO4'5H20 mg/L 2.07 0.1-100, 05-50, or 1-25 ‘ NiSO4'6H20 mg/L 2.07 0.1-100, 05-50, or 1-25 ‘Post autoclave iVitaminsl A Thiamine mg/L '9.75 0.1-100, 1-50, or 5-25 Vitamin B12 mgL 0.16 0.01-100, 0.05-5, or 0.1-1 Ca‘A-pantothenate mg/L 2.06 0.1-100, 01-50, or 1-10 Biotin mg/L 3.21 0.1-100, 0.1-50, 0r1-10 2012/047731 - 12 _ Post autoclave (Carbon) Glycerol g/L 30.0 5—150, 10-100, or 20-50 Nitrogen Feed: Ingredient Concentration MSG'lHZO g/L 17 0-150, 10-100, or 15-50 Typical cultivation conditions would include the following: pH about 6.5 — about 9.5, about 6.5 — about 8.0, or about 6.8 - about 7.8; temperature: about 15 — about 30 degrees Celsius, about 18 — about 28 ' s s, or about 21 to about 23 degrees Celsius; dissolved oxygen: about 0.1 — about 100% saturation, about 5 — about 50% saturation, or about 10 — about 30% saturation; and/or glycerol controlled @: about 5 — about 50 g/L, about 10 — about 40 g/L, or about —about 35 g/L.

In some embodiments, the microorganism deposited under ATCC Accession No.

PTA-10212, or a mutant, variant, or recombinant thereof, grows heterotrophically on glycerol as the carbon source but does not grow on glucose as the carbon source.

A l media for growth of the microorganism deposited under ATCC Accession No. PTA-10208 is shown in Table 2: Table 2: PTA-10208 Vessel Media Ingredient concentration ran es Na2S04 g/L 8.8 0-25, 2-20, or 3-10 NaCl g1. 0.625 0-25, 0.1-10, or 0.5-5 KCl g/L » 1.0 0-5, 0.25—3, or 0.5-2 MgSO4'7H20 g/L 5.0 0-10, 2-8, or 3-6 (NH4)2SO4 g/L 0.42 0-10, 0.25-5, or 0.05-3 CaClz 0.29 . g/L 0.1-5, 0.15-3, or 02-] T 154 (yeast extract) g/L 1.0 0-20, , or 0.5-5 KH2P04 g/L 1.765 , 05—5, or 1-3 Post ave (Metals) , Citric acid mg/L 46.82 0.1-5000, 10-3000, or 40-2500 FeSO4'7HzO mg/L 10.30 0.1-100, 1-50, or 5-25 MnClz‘4H20 mg/L 3.10 0.1-100, 1-50, or 2-25 ZnSO4'7H20 mg/L 9.3 001-100, 1-50, or 2—25 CoClz'6H20 mg/L 0.04 0-1, 0001-01, or 0.01-O.l - 13 _ NazMoO4'2H20 mg/L 0.04 0001-], 0005-05, or 001—0.] CuSO4'5H20 mg/L 2.07 0.1-100, 05-50, or 1-25 NiSO4'6H20 mg/L 2.07 0.1-100, 05-50, or 1-25 Postautoclave (Vitamins), Thiamine mg/L 9.75 0.1-100, 1-50, or 5-25 pantothenate mg/L 3.33 0.1-100, 01-50, or 1-10 Biotin mg/L 3.58 0.1-100, 01-50, or 1-10 Post autoclave (Carboni Glucose g/L 30.0 5-150, 10-100, or 20-50 en Feed: Ingredient Concentration NH4OH mL/L 23.6 0-150, , or 15-50 Typical cultivation conditions would include the ing: pH about 6.5 — about 8.5, about 6.5 — about 8.0, or about 7.0 — ‘ about 8.0; ature: about 17 — about 30 degrees Celsius, about 20 — about 28 degrees Celsius, or about 22 to about 24 degrees Celsius; dissolved oxygen: about 2 — about 100% saturation, about 5 — about 50% saturation, or about 7 — about 20% saturation; and/or glucose controlled @: about 5 — about 50 g/L, about 10 — about 40 g/L, or about — about 35 g/L.

In some embodiments, the culture medium comprises at least about 0.1%, at least about 0.5%, at least about 1%, at least about 1.5%, at least about 2%, at least about 5%, at least about 7%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% dissolved oxygen, -as a percentage of saturation level. In some embodiments, the culture medium comprises about 0.1% to about 2%, about 0.1% to about 5%, about 0.1% to about 10%, about 0.1% to about 20%, about 0.1% to about 30%, about 0.1% to about 50%, about 0.1% to about 100%, about 5% to about 10%, about 5% to about 20%, about 5% to about 30%, about 5% to about 50%, about 5% to about 100%, about 7% to about 10%, about 7% to about 20%, about 7% to about 30%, about 7% to about 50%, about 7% to about 100%, about 10% to about 20%, about 10% to about 30%, about 10% to about 50%, about 10% to about 100%, about 20% to abOUt 30%, about 20% to about 50%, or about 20% to about 100% dissolved oxygen, as a percentage of saturation level.

The invention is directed to an isolated biomass of a microorganism of the invention. An isOlated biomass of the invention is a harvested cellular biomass obtained by any conventional method for the isolation of a s, such as described in US.

Patent No. 5,130,242 and US. Appl. Publ. No. 2002/0001833, each of which are incorporated by reference herein in its entirety.

In some embodiments, the dry cell weight of the biomass isolated fromeach liter of culture is at least about 10 g, at least about 15 g, at least about 20 g, at least about 25 ‘g, at least about 30 g, at least about 50 g, at least about 60 g, at least about 70 g, at least about 80 g, at least about 100 g, at least about 120 g, at least about 140 g, at least about 160 g, at least about 180 g, or at least about 200 g after growing for about 6 days to about 8 days at about 15°C to about 30°C in a culture medium of about pH 6.5 to about 9.5 comprising sources of carbon, nitrogen, and nutrients, and about 950 ppm to about 8500 ppm chloride ions. In some embodiments, the dry cell weight of the s isolated from each liter of culture is at least about 10 g, at least about 15 g, at least about 20 g, at least about 25 g, at least about 30 g, at least about 50 g, at least about 60 g, at least about 70 g, at least about 80 g, at least about 100 g, at least about 120 g, at least about 140 g, at least about 160 g, at least about 180 g, or at least about 200 g after g for about 6 days, about 7 days, or about 8 days at about 15°C, about 16°C, about 17°C, at about 18°C, at about 19°C, at about 20°C, at about 21°C, at about 22°C, at about 23°C, at about 24°C, at about 25°C, at about 26°C, at about 27°C, at about 28°C, at about 29°C, or at about 30°C in a e medium of about pH 6.5, about pH 7, about pH 7.5, about pH 8.0, about pH 8.5, about pH 9, or about pH 9.5 comprising sources of , nitrogen, and nutrients, and about 950 ppm to about 8500 ppm de ions. In some embodiments, the dry cell weight of the biomass isolated from each liter of culture is about 10 g to about 200 g after growing for about 6 days to about 8 days at about 15°C to about 30°C in a culture medium of about pH 6.5 to about pH 9.5 comprising sources of carbon, nitrogen, and nutrients, and about 950 ppm to about 8500 ppm chloride ions. In some embodiments, the dry cell weight of the biomass isolated from each liter of culture is about 10 g to about 200 g,,about 10 g to about 100 g, about 10 g to about 50 g, about 15 g about to about 200 g, about 15 g to about 100 g, about 15 g to about 50 g, about 20 g to 200 g, about 20 g to about 100 g, about 20 g to about 50 g, about 50 g to about 200 g, or about 50 g to about 100 g aﬁer growing for about 6 days, about 7 days, or about 8 days at about 15°C, about 16°C, about 17°C, at about 18°C, at about 19°C, at about 20°C, at about 21°C, at about 22°C, at about 23°C, at about 24°C, at about 25°C, at about 26°C, at about 27°C, at about 28°C, at about 29°C, or at about 30°C in a culture medium of about pH 6.5, about pH 7, about pH 7.5, about pH 8.0, about pH 8.5, about pH 9, or about pH 9.5 comprising sources of carbon, nitrogen, and nutrients, and about 950 ppm to about 8500 ppm de ions. In some embodiments, the isolated culture does not contain polyvinylpyrrolidone.

In some embodiments, the isolated culture has an omega-3 fatty acid productivity of at least about 0.2 g/L/day, at least about 0.3 g/L/day, at least about 0.4 g/L/day, at least about 0.5 g/L/day, at least. about 1 g/L/day, at least about 1.2 g/L/day, at least about 1.5 g/L/day, at least about 1.7 g/L/day, at least about 2 g/L/day, at least about 3 g/L/day, at least about 3.5 g/L/day, at least about 4 g/L/day, at least about 4.5 g/L/day, at least about g/L/day, at least about 6 g/L/day, or at least about 8 y after growing for about 6 days, about 7 days, or about 8 days at about 15°C to about 30°C in a culture medium of about pH 6.5 to about pH 8.5 or about pH 6.5 to about pH 9.5 comprising s of carbon, nitrogen, and nutrients, and about 950 ppm to about 8500 ppm chloride ions. In some ments, the isolated culture has an omega-3 fatty acid productivity of about 0.2 y to about 20 g/L/day, about 0.4 g/L/day to about 20 g/L/day, about 0.4 g/L/day to about 2 g/L/day, about 1 g/L/day to‘about 2 g/L/day, about 1 g/L/day to about 20 g/L/day, about 2 g/L/day to about 15 g/L/day, about 2 g/L/day to about 10 g/L/day, about 3 y to about 10 g/L/day, about 4 g/L/day to about 9 g/L/day, about 4 y to about 8 g/L/day, about 4 g/L/day to about 7 g/L/day, or about 4 g/L/day to about 6 g/L/day after growing for about 6 days, about 7 days, or about 8 days at about 15°C to about 30°C in a culture medium of about pH 6.5 to about pH 9.5 comprising sources of carbon, nitrogen, and nutrients, and about 950 ppm to about 8500 ppm chloride ions.

In some embodiments, the isolated culture comprises an EPA productivity of at least about 0.2 g/L/day, at least about 0.3 y, at least about 0.4 y, at least about 0.5 g/L/day, at least about 0.6 g/L/day, at least about 0.7 g/L/day, at least about 0.8 g/L/day, at least about 0.9 g/L/day, at least about 1 g/L/day, at least about 1.2 g/L/day, at least about 1.5 g/L/day, at least about 1.7 g/L/day, at least about 2 g/L/day, at least about 3 g/L/day, at least about 4 g/L/day, or at least about 5 g/L/day after growing for about 6 days, about 7 days, or about 8 days at about 15°C to about 30°C in a culture medium of about pH 6.5 to about pH 8.5 or about pH 6.5 to abont pH 9.5 comprising sources of carbon, en, and nutrients, and about 950 ppm to about 8500 ppm chloride ions. In some embodiments, the EPA productivity is about 0.2 g/L/day to about 5 g/L/day, about 0.2 g/L/day to ab0ut 4 g/L/day, about 0.2 g/L/day to about 3 y, about 0.2 g/L/day to about 2 y, about 0.2 g/L/day to about 1 g/L/day, about 0.2 g/L/day to about 0.8 g/L/day, about 0.2 g/L/day to about 0.7 g/L/day, about 1 g/L/day to about 5 y, about 1 g/L/day to about 4 g/L/day, about 1 g/L/day to about 3 y, or about 1 g/L/day to about 2 g/L/day after growing for about 6 days, about 7 days, or about 8 days at about 15°C to about 30°C in a culture medium of about pH 6.5 to about pH 8.5 or about pH 6.5 to about pH 9.5 comprising sources of carbon, nitrogen, and nutrients, and about 950 ppm to about 8500 ppm chloride ions. In some embodiments, any of the aforementioned EPA productivities areassociated with any of the aforementioned omega- 3 fatty acid productivities. In some embodiments, the culture further comprises a DHA productivity of about 0 g/L/day to about 5 g/L/day, about 0 g/L/day to about 4 g/L/day, about 0 g/L/day to about 3 g/L/day, about 0 g/L/day to about 2 g/L/day, about 0 g/L/day to about 1 g/L/day, about 0.2 y to about 5 g/L/day, about 0.2 g/L/day to about 4 y, about 0.2 g/L/day to about 3 g/L/day, about 0.2 g/L/day to about 2 y, about 0.2 g/L/day to about ilz'g/L/day, about 1 g/L/day to about 5 g/L/day, about 2 g/L/day to about 5 g/L/day, about 2 g/L/day to about 4 g/L/day, or about 2 g/L/day to about 3 g/L/day. In some ments, the DHA productivity is less than about 5 g/L/day, less than about 4 g/L/day, less than about 3 g/L/day, less than about 2 g/L/day, less than about 1 g/L/day, less than about 0.5 g/L/day, less than about 0.2 g/L/day, or about 0 g/L/day.

In some embodiments, the fermentation volume (volume of culture) is at least about 2 liters, at least about 10 liters, at least about 50 liters, at least about 100 liters, at least about 200 liters, at least about 500 liters, at least about 1000 liters, at least about ,000 , at least about 20,000 liters, at least about 50,000 , at least about 100,000 liters, at least about 150,000 liters, at least about 200,000 liters, or at least about 0 liters. In some embodiments, the fermentation volume is about ‘2 liters to about 300,000 liters, about 2 liters, about 10 liters, about 50 liters, about 100 liters, about 200 liters, about 500 liters, about 1000 liters, about 10,000 liters, about 20,000 liters, about 50,000 liters, about 100,000 liters, about 150,000 , about 0 , about 250,000 liters, or about 300,000 liters.

In some embodiments, the invention is directed to an isolated biomass sing a fatty acid proﬁle of the invention. In some embodiments, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, or at least about 80% of the dry cell weight of the biomass are fatty acids. In some ments, greater than about 20%, greater than about 25%, than greater than about 30%, greater than about 35%, greater than about 40%, greater about 45%, greater than about 50%, greater than about 55%, or greater than about 60% of the dry cell weight of the biomass are fatty acids. In some embodiments, about 20% to about 55%, about‘20% to about 60%, about 20% to about 70%, about 20% to about 80%, about 30% to about 55%, about 30% to about 70%, about 30% to about 80%, about 40% to about 60%, about 40% to about 70%, about 40% to about 80%, about 50% to about 60%, about 50% to about 70%, about 50% to about 80%, about 55% to about 70%, about 55% to about 80%, about 60% to about 70%, or about 60% to about 80% by weight of the dry cell Weight of the biomass are fatty acids. In some embodiments, the biomass comprisesmore than about 10%, at least about 12%, at least about 15%, at least about %, at least about 25%, at least about 30%, about least about 35%, at least about 40%, or at least about 45% by weight of the fatty acids as EPA. In some embodiments, the biomass comprises about 10% to about 55%, about 12% to about 55%, about 15% to about 55%, about 20% to about 55%, about 20% to about 40%, or about 20% to about % by weight of the fatty acids as EPA. In some embodiments, the s comprises a triacylglycerol fraction, wherein at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 16%, at least about 17%, at least about 18%, at least about 19%, or at least about 20% by weight 012‘ the triacylglycerol fraction is EPA.

In some embodiments, the biomass comprises a triacylglycerol fraction, wherein the EPA content of the triacylglycerol fraction is from at least about 12% to about 55%, about 12% to about 50%, about 12%‘tqtabout 45%, at least about 12% to about 40%, at least about 12% to about 35%, or at least about 12% to about 30%, about 15% to about 55%, about % to about 50%, about 15% to about 45%, about 15% to about 40%, about 15% to about 35%, about 15% to about 30%, about 20% to about 55%, about 20% to about 50%, -l8- about 20% to about 45%, at least about 20% to about 40%, at least about 20% to about %, or about 20% to about 30% by weight. In some embodiments, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, or at least about 60% by weight of the dry cell weight of the biomass is DHA.

In some embodiments, about 20% to about 60%, about 25% to about 60%, about 25% to about 50%, about 25% to about 45%, about 30% to about 50%, or about 35% to about 50% by weight of the dry cell weight of the biomass is DHA. In some embodiments, the biomass comprises about 10% or less, about 9% or less, about 8% or less, about 7% or less, about 6% or less, about 5% or less, about 4% or less, about 3% or less, about 2% or less, or about 1% or less by-‘weight of the fatty acids as DHA. 'In some embodiments, the biomass ses about 1% to about 10%, about 1% to about 5%, about 2% to about %, about 3% to about 5%, or about 3% to about 10% by weight of the fatty acids as DHA. In some embodiments, the biomass is ntially free of DHA. In some embodiments, the biomass comprises about 0.1% to less than about 5%, about 0.1% to about 4%, about 0.1% to about 3%, about 0.1% to about 2%, about 0.2% to less than about 5%, about 0.2% to about 4%, about 0.2% to about 3%, about 0.2% to about 2%, about 0.3% to about 2%, about 0.1% to about 0.5%, about 0.2% to about 0.5%, about 0.1% to about 0.4%, about 0.2% to about 0.4%, about 0.5% to about 2%, about 1% to about 2%, about 0.5% to about 1.5%, or about 1% to about 1.5% by weight of the fatty acids as ARA. In some embodiments, the biomass comprises less than about 5%, about 4% or less, about 3% or less, about 2% or less, about 1.5% or less, about 1% or less, about 0.5% or less, about 0.4% or less, about 0.3% or less, about 0.2% or less, or about 0.1% or less by weight of the fatty acids as ARA. In some embodiments, the biomass is ntially free of ARA. In some embodiments, the biomass comprises about 0.4% to about 2%, about 0.4% to about 3%, about 0.4% to about 4%, about 0.4% to about 5%, about 0.4% to less than about 5%, about 0.5% to about 1%, about 0.5% to about 2%, about 0.5% to about 3%, about 0.5% to about 4%, about 0.5% to about 5%, about 0.5% to less than about 5%, about 1% to about 2%, about 1% to about 3%, about 1% to about 4%, about 1% to about 5%, or about 1% to less than about 5% by weight of the fatty acids as DPA n-6. In some embodiments, the biomass comprises about 5% or less, less than about %, about 4% or less, about 3% or less, about 2% or less, about 1% or less, about 0.75% the fatty acids as DPA n-6. or less, about 0.6% or less, or about 0.5% or less by weight of In some ments, the biomass is substantially free of DPA n-6. In some embodiments, the biomass comprises fatty acids with about 5% or less, less than about %, about 4% or less, about 3% or less, or about 2% or less by weight of oleic acid (18:1 n-9), linoleic acid (18:2 n-6), nic acid (18:3 n-3), eicosenoic acid (20:1 n-9), erucic acid (22:1 ":9): or ations thereof.

The characteristics of an isolated biomass of the invention are associated with endogenous or native properties of the isolated biomass rather than exogenously introduced materials. In some embodiments, the ed biomass does not contain nylpyrrolidone or is not isolated from a culture containing polyvinylpyrrolidone. [0061'] The present invention is directed to a method of producing a biomass. In some embodiments, the method for producing a biomass of the invention comprises growing mixtures thereof in a culture to any of the isolated microorganisms of the invention or produce a biomass. The present invention is directed to a biomass produced by the method.

The invention is directed to a microbial oil comprising a fatty acid proﬁle of the invention. A microbial oil of the invention is a "crude oil" or a "reﬁned oil" sing a triacylglycerol fraction of at least about 35% by weight. A "crude oil" is an oil that is extracted from the biomass of the microorganism without further processing. A "reﬁned oil" is an oil that is obtained: by treating a crude oil with standard processing of reﬁning, bleaching, and/or izing. See, e.g., US. Patent No. 5,130,242, orated by reference herein in its entirety. A microbial oil also includes a "ﬁnal oil" as described herein, which is a reﬁned oil that has been diluted with a vegetable oil. In some embodiments, a ﬁnal oil is a reﬁned oil that has been d with high oleic sunﬂower oil: The term "microbial" as used herein includes, but is not limited to, the terms "microalgal," stochytrid," and taxonomic classiﬁcations associated with any of the deposited microorganisms described herein. The terms "Thraustochytriales," "thraustochytrid," "Schizochytrium," and "Thraustochytrium" as used in reference to any of the microbial oils of the deposited microorganisms bed herein are based on present taxonomic classiﬁcations including available phylogenetic information and are not intended to be limiting in the event that the mic classiﬁcations are revised after the ﬁling date of the present application.

In some embodiments, a fatty acid as described herein can be a fatty acid ester. In some embodiments, a fatty acid ester includes an ester of an omega-3 fatty acid, 6 fatty acid, and combinations thereof. In some embodiments, the fatty acid ester is a DHA ester, an EPA ester, or a ation thereof. In some ments, an oil or fraction thereof as described herein is esteriﬁedto produce an oil or on thereof comprising fatty acid esters. The term "ester" refers to the replacement of the hydrogen in the carboxylic acid group of the fatty acid molecule with another substituentr l esters are known to those in the art, a discussion of which is provided by Higuchi, T. and V.

Stella in Pro—drugs as Novel Delivery Systems, Vol. 14, A.C.S. Symposium Series, Bioreversible rs in Drug Design, Ed. Edward B. Roche, American ceutical Association, Pergamon Press, 1987, and Protective Groups in Organic Chemistry, ' McOmie ed., Plenum Press, New York, 1973. Examples of esters e methyl, ethyl, propyl, butyl, pentyl, t-butyl, benzyl, nitrobenzyl, methoxybenzyl, benzhydryl, and trichloroethyl. In some embodiments, the ester .is a carboxylic acid protective ester group, esters with aralkyl (e.g., benzyl, phenethyl), esters with lower alkenyl (e.g., allyl, 2- butenyl), esters with lower~alkoxy-lower—alky1 (e.g., methoxymethyl, 2-methoxyethyl, 2— ethoxyethyl), esters with lower—alkanoyloxy-lower-alkyl (e.g., acetoxymethyl, yloxymethyl, l-pivaloyloxyethyl), esters with lower-alkoxycarbonyl-lower-alkyl (e.g., methoxycarbonylmethyl, isopropoxycarbonylmethyl), esters with carboxy-lower alkyl (e.g., carboxymethyl), esters with lower-alkOxycarbonyloxy-lower-alkyl (e.g., 1— (ethoxycarbonyloxy)ethyl, 1-(cyclohexyloxycarbonyloxy)ethyl), esters with carbamoyloxy-lower alkyl (e.g., carbamoyloxymethyl), and the like. In some embodiments, the added substituent is a linear or cyclic hydrocarbon group, e.g., a C1-C6 alkyl, Cl-C6 cycloalkyl, C1-C6 alkenyl, or Cl-C6 aryl ester. In some embodiments, the ester is an alkyl ester, e.g., a methyl ester, ethyl ester or propyl ester. In some embodiments, the ester substituent is added to the free fatty acid molecule when the fatty acid is in a puriﬁed or semi-puriﬁed state. Alternatively, the fatty acid ester is formed upon conversion of a triacylglycerol to an ester.

The t invention is directed to methods of producing microbial oils. In some embodiments, the method comprises growing any of the isolated microorganisms of the invention or es thereof in a culture to produce a microbial oil comprising omega-3 fatty acids. In some ments, the method further comprises extracting the microbial oil. In some embodiments, the method comprises extracting a microbial oil comprising omega-3 fatty acids from any of the biomasses of the invention or mixtures thereof. In some embodiments, the method comprises heterotrophically growing the isolated microorganism, wherein the culture comprises a carbon source as described herein. The microbial oil can be extracted from a ﬁeshly harvested biomass or can be ted from a previously harvested biomass that has been stored under conditions that prevent spoilage. Known methods can be used to culture a microorganism of the invention, to isolate a biomass from the culture, to extract a microbial oil from the s, and to analyze the fatty acid proﬁle of oils extracted from the biomass. See, e.g., US. Patent No. 5,130,242, incorporated by reference herein in its ty. The invention is directed to a microbial oil produced by any of the methods of the invention. in some embodiments, the microbial oil is extracted by an enzyme extraction method. In some embodiments, the microbial oil is extracted by a mechanical extraction method. In some embodiments, the mechanical extraction method comprises one or more of: (1) processing a pasteurized fermentation broth through a homogenizer to assist in cell lysis and release of oil from cells; (2) adding isopropyl alcohol to the fermentation broth following homogenization to break the oil and water emulsion; (3) centrifuging the mixture to recover the oil phase; and (4) drying under vacuum with addition of antioxidants. In some embodiments, the crude oil is puriﬁed. In some embodiments, puriﬁcation of the crude oil comprises one or more of: (1) pumping the crude oil into a reﬁning tank and heating the oil, followed by adding an acid solution with mixing; (2) adding a caustic on to the oil after acid treatment; (3) reheating the crude oil and then centrifuging to te the heavy phase from the reﬁned oil; (4) ng the ing polar compounds, trace metals, and oxidation ts from the reﬁned oil by using, for example, acid, TriSyl®, clay, and/or ﬁltration; (5) chill ﬁltering the ed oil (if) further remove high melting point components from the oil to achieve the desired level of y; (6) heating the oil, aﬁer which the oil is then cooled and held for a period of time g the high melting triglycerides and waxes to crystallize; (7) adding a ﬁlter aid to the d oil and then removing llized solids by ﬁltration; (8) using a deodorizer aﬁer chill ion, operated under high temperature and vacuum, to remove, for example, peroxides and any remaining low molecular weight compounds that can cause off-odor and ﬂavors; (9) transferring the oil to the deodorizer feed tank, deaerating, and deodorizing, for e, in a packed column izer; and (10) cooling, for example, under a nitrogen blanket at the end of the deodorization cycle and adding suitable antioxidants to the deodorized oil to provide oxidative stability.

In some ments, the microbial oil comprises a sterol esters fraction of about 0%, at least about 0.1%, at least about 0.2%, at least about 0.5%, at least about 1%, at least about 1.5%, at least about 2%, or at least about 5% by weight. In some ments, the microbial oil comprises a sterol esters fraction of about 0% to about 1.5%, about 0% to about 2%, about 0% to about 5%, about 1% to about 1.5%, about 0.2% to about 1.5%, about 0.2% to about 2%, or about 0.2% to about 5% by weight. In some embodiments, the microbial oil comprises a sterol esters fraction of about 5% or less, about 4% or less, about 3% or less, about 2% or less, about 1% or less, about 0.5% or less, about 0.3% or less, about 0.2% or less, about 0.5% or less, about 0.4% or less, about 0.3% or less, or about 0.2% or less by weight.

In some embodiments, the microbial oil comprises a triacylglycerol fraction of at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at' least about 75%, at least about 80%, at least about 85%, or at least about 90% by weight. In some embodiments, the microbial oil comprises a lglycerol fraction of about 35% to about 98%, about 35% to about 90%, about 35% to about 80%, about 35% to about 70%, about % to about 70%, about 35% to about 65%, about 40% to about 70%, about 40% to about 65%, about 40% to about 55%, about 40% to about 50%, about 65% to about 95%, about 75% to about 95%, about 75% to about 98%, about.80% to about 95%, about 80% to about 98%, about 90% to. about 96%, about 90% to about 97%, about 90% to about 98%, about 90%, about 95%, about 97%, or about 98% by weight.

In some embodiments, the microbial oil comprises a diacylglycerol fraction of at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 16%, at least about 17%, at least about 18%, at least about 19%, or at least about 20% by weight. In some embodiments, the ial oil comprises a diacylglycerol fraction of about 10% to about 45%, about 10% to about 40%, about 10% to about 35%, about 10% to about 30%, about 15% to about 40%, about % to about 35%, or about 15% to about 30% by weight. In some embodiments, the microbial oil comprises a 1,2-diacylglycerol fraction of at least about 0.2%, at least about 0.3%, at least about 0.4%, at least about 0.5%, at least about 1%, at least about 5%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, atleast about 16%, at least about 17%, at least about 18%, at least about 19%, or at least about 20% by weight. In some embodiments, the microbial oil comprises a diacylglycerol fraction of about 0.2% to about 45%, about 0.2% to about %, about 0.2% to about 20%, about 0.2% to about 10%, about 0.2% to about 5%, about 0.2% to about 1%, about 0.2% to about 0.8%, about 0.4% to about 45%, about 0.4% to about 30%, about 0.4% to about 20%, about 0.4% to about 10%, about 0.4% to about 5%, about 0.4% to about 1%, about 0.4% to about 0.8%, about 0.5% to about 1%, about 0.5% to about 0.8%, about 10% to about 45%, about 10% to about 40%, about 10% to about %, about 10% to about 30%, about 15% to about 40%, about 15% to about 35%, about % to about 30%, or about 15% to about 25% by weight. In some embodiments, the microbial oil comprises a 1,3-diacylglycerol fraction of at least about 0.1%, at least about 0.2%, at least about 0.5%, at least about 1%, at least about 2%, at least about 2.5 %, or at least about 3% by weight. In some embodiments, the microbial oil comprises a sterol fraction of at least about 0.3%, at least about 0.4%, at least about 0.5%, at least about 1%, at least about 1.5%, at least.'about 2%, or at least about 5% by .

In some embodiments, the microbial oil comprises a sterol fraction of about 0.3% to about 5%, about 0.3% to about 2%, about 0.3% to about 1.5%, about 0.5% to about %, about 1% to about 1.5%, about 0.5% to about 2%, about 0.5% to about 5%, about 1% to about 2%,.or about 1% to about 5% by weight. In some embodiments, the microbial oil ses a sterol fraction of about 5% or less, about 4% or less, about 3% or less, about 2% or less, about 1.5% or less, or about 1% or less by weight.

‘ In some embodiments, the microbial oil comprises a phospholipid fraction of at least about 2%, at least about 5%, or at least about 8% by weight. In some embodiments, the ial oil comprises a phospholipid fraction of about 2% to about 25%, about 2% to about 20%, about 2% to about 15%, about 2% to about 10%, about 5% to about 25%, about 5% to about 20%, about 5% to about 20%, about 5% to about 10%, or about 7% to about 9% by weight. In some embodiments, the microbial oil comprises a phOSpholipid fraction of less than about 20%, less than. about 15%, less than about 10%, less than about 9%, or less than about 8% by . In some embodiments, the microbial oil is substantially free of phospholipids. In some ments, the microbial oil comprises unsaponiflables of less than about 2%, less than about 1.5%, less than about 1%, or less than about 0.5% by weight of the oil. The lipid classes present in the microbial oil, such as a triacylglycerol fraction, can be separated by ﬂash chromatography and analyzed by thin layer chromatography (TLC), or separated and analyzed by other s known in the art.

In some embodiments, the microbial oil and/or one or more fractions thereof selected from the triacylglycerol fraction, the free fatty acid on, the sterol fraction, the diacylglycerol fraction, and ations thereof, comprises at least about 5%, at least about 10%, more than about 10%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 16%, at least about' 17%, at least about 18%, at least about 19%, at least about 20%, at least about 25%, at least about 30%, about least about 35%, at least about 40%, or at least about 45% by weight EPA. In some embodiments, the microbial oil and/or one or more fractions thereof selected from the triacylglycerol fraction, the free fatty acid fraction, the sterol fraction, the diacylglycerol fraction, and combinations f, comprises about 5% to about 55%, about 5% to about 50%, about 5% to about 45%, about 5% to about 40%, about 5% to about 35%, about 5% to about 30%, about 10% to about 55%, about 10% to about 50%, about 10% to about 45%, about 10% to about 40%, about 10% to about 35%, about 10% to about 30%, at least about 12% to about 55%, at least about 12% to about 50%, at least about 12% to about 45%, at least about 12% to about 40%, at least about 12% to about 35%, or at least about 12% to about 30%, about 15% to about 55%, about 15% to about 50%, about 15% to about 45%, about 15% to about 40%, about 15% to about 35%, about 15% to about %, about 15% to about 25%, about 15% to about 20%, about 20% to about 55%, about % to about 50%, about 20% to about 45%, about 20% to about 40%, or about 20% to about 30% by weight EPA. In some embodiments, the microbial oil and/or oneor more fractions thereof selected from the triacylglycerol fraction, the diacylglycerol fraction, the sterol fraction, the sterol esters fraction, the free fatty acids fraction, the phospholipid fraction, and combinations thereof, comprises at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about %, at least about 40%, at least about 50%, or at least about 60% by weight DHA. In from some embodiments, the microbial oil and/or one or more fractions f selected the lglycerol fraction, the diacylglyeerol fraction, the sterol fraction, the sterol esters fraction, the free fatty acids fraction, the phospholipid ﬁaction, and combinations thereof, comprises about 5% to about 60%, about 5% to about 55%, about 5% to about 50%, about 5% to about 40%, about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 20% to about 60%, about 25% to about 60%, about 25% to about 50%, about 25% to about 45%, about 30% to about 50%, about 35% to about 50%, or about % to about 40% by weight DHA. In some ments, the microbial oil and/or one or more fractions thereof selected from the triacylglycerol fraction, the diacylglycerol fraction, the sterol fraction, the sterol esters fraction, the free fatty acids fraction, the phospholipid fraction, and combinations thereof, comprises about 10% or less, about 9% about 4% or less, about 8% or less, about 7% or less, about 6% or less, about 5% or less, ‘ In some or less, about 3% or less, about 2% or less, or about 1% or less by weight DHA. embodiments, the ial oil and/or one or more fractions thereof selected from the triacylglyccrol fraction, the diacylglycerol fraction, the sterol fraction, the sterol esters fraction, the free fatty acids fraction, the phospholipid fraction, and ations thereof, comprises about 1% to about 10%, about 1% to about 5%, about 2% to about 5%, about 3% to about 5%, or about 3% to about 10% by weight of the fatty acids as DHA. In some embodiments, the microbial oil and/or one or more fractions thereof ed from the triacylglycerol fraction, the diacylglycerol fraction, the sterol fraction, the sterol esters fraction, the free fatty acids on, the phospholipid fraction, and combinations thereof, is substantially free of DHA. In some embodiments, the microbial oil and/or one or more fractions thereof selected from the triacylglycerol fraction, the diacylglycerol fraction, the sterol fraction, the sterol esters fraction, the free fatty acids fraction, the olipid fraction, and combinations thereof, comprises about 0.1% to about 5%, about 0.1% to less than about 5%, about 0.1% to about 4%, about 0.1% to about 3%, about 0.1% to about 2%, about 0.2% to about 5%, about 0.2% to less than about 5%, about 0.2% to about 4%, about 0.2% to about 3%, about 0.2% to about 2%, about 0.3% to about 2%, about 0.1% to about 0.5%, about 0.2% to about 0.5%, about 0.1% to about 0.4%, about 0.2% to about 0.4%, about 0.5% to about 2%, about 1% to about 2%, about 0.5% to about 1.5%, or about 1% to about 1.5% by weight ARA. In some embodiments, the ial oil and/or one or more fractions thereof ed from the triacylglycerol fraction, the diacylglycerol fraction, the sterol fraction, the sterol esters on, the free fatty acids fraction, the phospholipid fraction, and combinations thereof, comprises about 5% or less, less than about about 5%, about 4% or less, about 3% or less, about 2% or less, about. 1.5% or less, 1% or less, about 0.5% or less, about 0.4% or less, about 0.3% or less, about 0.2% or less, or about 0.1% or less by weight ARA. In some embodiments, the microbial oil and/or one or more fractions thereof selected from the triacylglycerol fraction, the diacylglycerol fraction, the sterol fraction, the sterol esters fraction, the free fatty acids fraction, the phospholipid fraction, and combinations thereof, is substantially free of ARA. In some embodiments, the ial oil and/or one or more fractions thereof selected from the lglycerol fraction, the diacylglycerol fraction, the sterol fraction, the sterol esters on, the free fatty acids fraction, the olipid on, and combinations thereof, comprises about 0.4% to about 2%, about 0.4% to about 3%, about 0.4% to about 4%, about 0.4% to about 5%, about 0.4% to less than about 5%, about 0.5% to about 1%, about 0.5% to about 2%, about 0.5% to about 3%, about 0.5% to about 4%, about 0.5% to about 5%, about 0.5% to less than about 5%, about 1% to about 2%, about 1% to about 3%, about 1% to about 4%, about 1% to about 5%, or about 1% to less than about 5% by weight DPA n-6. In some embodiments, the microbial oil and/or one or more fractions thereof selected from the triacylglycerol fraction, the diacylglycerol fraction, the sterol fraction, the sterol esters fraction, the free fatty acids fraction, the phospholipid fraction, and combinations thereof, comprises about 5%, less than about 5%, about 4% or less, about 3% or less, about 2% or less, about 1% or less, about 0.75% or less, about 0.6% or less, or about 0.5% or less by weight DPA n-6. In some ments, the microbial oil and/or one or more fractions thereof selected from the triacylglycerol fraction, the diacylglycerol fraction, the sterol fraction, the sterol esters fraction, the free fatty acids fraction, the phospholipid fraction, and combinations f, is substantially free of DPA n—6. In some embodiments, the microbial oil and/or one or more ons thereof selected from the triacylglycerol fraction, the diacylglycerol fraction, the sterol fractiOn, the sterol esters fraction, the free fatty acids on, the phospholipid fraction, and combinations thereof, comprises fatty acids with about 5% or less, less than about 5%, about 4% or less, about 3% or less, or about 2% or less by weight of oleic acid (18:1 n-9), linoleic acid (18:2 n-6), linolenic acid (18:3 n-3), eicosenoic acid (20:1 n-9), erucic acid (22:1 n-9), stearidonic acid (18:4 n-3), or combinations thereof.

The triacylglycerol molecule contains 3 central carbon atoms (C(sn-1)H2R1-(sn- 2)H2R2-C(sn-3)H2R3), allowing for formation of ent positional isomers. In some embodiments, the microbial oil comprises a triacylglycerol fraction in which at least about 2%, at least about 3%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 30%, at least about 35%, or at least about 40% of the tn'acylglycerols in the triacylglycerol fraction contain DHA at two positions in the triacylglycerol (di-substituted DHA) selected from any two of the sn-1, sn-2, and sn-3 positions, based on the relative area percent of peaks on an HPLC chromatograph. In in which about some embodiments, the ial oil comprises a triacylglycerol on 2% to about 55%, about 2% to about 50%, about 2% to about 45%, about 2% to about . 40%, about 2% to about 35%, about 2% to about 30%, about 2% to about 25%, about 5% to about 55%, about 5% to about 50%, about 5% to about 45%, about 5% to about 40%, about 5% to about 35%, about 5% to about 30%, about 5% to about 25%, about 10% to about 55%, about 10% to about 50%, about 10% to about 45%, about 10% to about 40%, about 10% to about 35%, about 10% to about 30%, about 10% to about 25%, about 10% to about to about 20%, about 20% to about 40%, about 20% to about 35%, or about 20% % of the triacylglycerOls in the triacylglycerol fraction contain EPA at two positions in the triacylglycerol selected from any two of the sn-1, sn-2, or sn-3 positions, based on the relative area percent of peaks on an HPLC chromatograph. In some embodiments, the microbial oil ses a triacylglycerol on in which at least about 0.5%, at least about 1%, at least about 1.5%, or at least about 2% of the triacylglycerols in the triacylglycerol fraction contain DHA at all of the sn-1, sn-2, and sn-3 positions (tri- substituted DHA), based on the relative area percent of peaks on an HPLC chromatograph. In some embodiments, the microbial oil comprises a triacylglycerol fraction in which about 0.5% to about 5%, about 0.5% to about 3%, about 0.5% to about 2.5%, about 0.5% to about 2%, about 1% to about 5%, about 1% to about 3%, or about 1% to about 2% of the triacylglycerols in the triacylglycerol fraction n DHA at all of the sn-1, sn-2, and sn-3 positions, based on the relative area percent of peaks on an HPLC chromatograph. In some embodiments, the microbial oil comprises a triacylglycerol fraction in which at least about 10%, at least about 15%, at least about %, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, or at least about 60% of the triacylglycerols in the triacylglycerol fraction contain DHA at one position in the triacylglycerol selected from any one of the sn-1, sn-2, or sn-3 positions, based on the relative area percent of peaks on an HPLC chromatograph. In some embodiments, the microbial oil comprises a triacylglycerol fraction in which about 10% to about 80%, about 10% to about 70%, about 10% to about 60%, about 15% to about 80%, about 15% to about to about 75%, about 15% to about 70%, about 15% to about 65%, about 15% 60%, about 35% to about 80%, about 35% to about 75%, about 35% to about 65%, about % to about 60%, about 40% to about 80%, about 40% to about 75%, about 40% to about 70%, about 40% to'about 65%, about 40% to about 60%, or about 40% to about 55% of the triacylglycerols in the triacylglycerol on contain DHA at one position in the triacylglycerol ed from any one of the sn-1, sn-2, and sn-3 positions, based on the relative area percent of peaks on an HPLC chromatograph.

In some embodiments the microbial oil ses fatty acids wherein the fatty acids further se, omega-3 polyunsaturated fatty acids wherein the omega-3 polyunsaturated fatty acids comprise DHA and EPA in an amount of about 290%, by weight, of the total amount of omega-3 polyunsaturated fatty acids and the amount of EPA, by weight, is from about 28% to about 36% of the total amount of DHA and EPA, and the amount of DHA, by weight, is from about 54% to about 62% of the total amount of DHA and EPA.

In another embodiment, microbial oil comprises omega-3 polyunsaturated fatty acids comprising DHA and EPA in an amount of about 290%, by weight, of the total amount of omega-3 polyunsaturated fatty acids, wherein the amount of EPA, by weight, is from about 19% to about 55% of the total amount of DHA and EPA, and the amount of DHA, by weight, is from about 35% to about 71% of the total amount of DHA and EPA.

In other embodiments, the microbial oil comprises omega-3 polyunsaturated fatty acids comprising DHA and EPA in an amount of about 290%, by weight, of the total amount of omega—3 polyunsaturated fatty acids, n the amount of EPA, by weight, is from about 19% to about 43% of the total amount of DHA and EPA, and the amount of DHA, by weight, is from about 35% to about 47% of the total amount of DHA and EPA.

In a further embodiment, the microbial oil comprises omega-3 polyunsaturated fatty acids comprising DHA and EPA in an amount of about 290%, by weight, of the total amount of omega-3 polyunsaturated fatty acids, wherein the amount of EPA, by , is from about 27% to about 54% of the total amount of DHA and EPA, and the amount of DHA, by weight, is from about 36% to about 63% of the total amount ofDHA and EPA.

WO 13211 In yet a further embodiment, the microbial oil comprises omega-3 polyunsaturated fatty acids comprising DHA and EPA in an amount of about 390%, by weight, of the total amount of omega-3 polyunsaturated fatty acids, wherein the amount of EPA, by weight, is from about 26% to about 38% of the total amount of DHA and EPA, and the amount of DHA, by weight, is from about 52% to about 64% of the total amount ofDHA and EPA.

In yet another embodiment, the microbial oil comprises omega-3 polyunsaturated fatty acids comprising DHA and EPA in an amount of about 390%, by weight, of the total amount of omega—3 polyunsaturated fatty acids, and DPA n-3 in an amount of from about 0% to about 10%, by weight,-of the total amount of omega-3 polyunsaturated fatty acids, wherein the amount of EPA, by weight, is from about 19% to about 55% of the total amount of DHA and EPA, and the amount of DHA, by weight, is from about 35% to about 71% of the total amount of DHA and EPA. in a still further embodiment, the microbial oil comprises 3 polyunsaturated fatty acids comprising DHA and EPA in an amount of about 390%, by , of the total amount of omega-3 polyunsaturated fatty acids, and DPA n—3 in an amount of from about 0% to about 10%, by weight, of the total amount of omega-3 polyunsaturated fatty acids, wherein the amount of EPA, by weight, is from about 19% to about 43% of the total amount of DHA and EPA, and the amount of DHA, by weight, is from about 35% to about 47% of the total amount of DHA and EPA.

In yet still r embodiment, the microbial oil comprises omega-3 polyunsaturated fatty acids comprising DHA and EPA in an amount of about 390%, by weight, of the total amount of omega-3 saturated fatty acids, and DPA n-3 in an amount of from about 0% to about 10%, by weight, of the total amount of omega-3 polyunsaturated fatty acids, n the amount of EPA, by weight, is from about 27% to about 54% of the total amount of DHA and EPA, and the amount of DHA, by weight, is from about 36% to about 63% of the total amount of DHA and EPA.

In another embodiment, the microbial oil comprises omega-3 polyunsaturated fatty acids comprising DHA and EPA in an amount of about 390%, by weight, of the total amount of omega-3 saturated fatty acids, and DPA n-3 in an amount offrom about 0% to about 10%, by weight, of the total amount of Omega-3 polyunsaturated fatty acids, wherein the amount of EPA, by weight, is from about 26% to about 38% of the total amount of DHA and EPA, and the amount of DHA, by.weight, is from about 52% to about 64% of the total amount of DHA and EPA.

In another embodiment, the ial oil comprises omega-3 polyunsaturated fatty acids comprising DHA and EPA in an amount of about _>_90%, by weight, of the total amount of omega-3 polyunsaturated fatty acids, and DPA n-3 in an amount of from about 0% to about 10%, by weight, of the total amount of omega-3 polyunsaturated fatty acids, wherein the amount of EPA, by weight, is from about 28% to about 36% of the total amount of DHA and EPA and the amount ‘of DHA, by , is from about 54% to about 62% ofthe total amount of DHA and EPA.

In yet another embodiment, the microbial oil comprises omega-3 polyunsaturated fatty acids comprising DHA and EPA in an amount of about 290%, by weight, of the total amount of omega-3 polyunsaturated fatty acids, and DPA n-3 in an amount of from about 0% to about 2%, by weight, of the total. amount of omega-3 polyunsaturated fatty acids, wherein the amount of EPA, by weight, is from about 10% to about 25% of the total amount of DHA and EPA and the amount of DHA, by weight, is from about 75% to about 90% of the total amount of DHA and EPA. |0084] In some embodiments, the total amount of omega-3 polyunsaturated fatty acids in the ial oil is at least about 400 mg per one gram of oil.

In other embodiments, the total amount of omega-3 polyunsaturated fatty acids in the microbial oil is at least about 500 mg per one gram of oil.

In still further embodiments, the total amount of 3 polyunsaturated fatty acids in the microbial oil is from about 400 mg to about 750 mg per one gram of oil.

In some embodiments, the ial oil comprises from about 120 mg to about 220 mg EPA per one gram of oil and from about 240 mg to about 450 mg DHA per one gram of oil.

In some embodiments, the microbial oil comprises from about 120 mg to about 220 mg EPA per one gram of oil and from about 240 mg to about 450 mg DHA per one gram of oil.

In other embodiments, the microbial oil comprises from about 130 mg to about 195 mg EPA per one gram of oil and from about 320 mg to about 480 mg DHA per one gram of oil.

In a further embodiment, the microbial oil comprises from about 150 mg to about 300 mg EPA per one gram of oil; from about 200 mg to about 400 mg DHA per one gram of oil; and from about 0 to about 55 mg DPA n-3 per one gram of oil.

In a still further embodiment, the microbial oil comprises from about 50 mg to about 150 mg EPA per one gram of oil; from about 410 mg to about 540 mg DHA per of oil one gram of oil; and from about _0 to about 12 mg DPA n-3 per one gram In some embodiments, the ial 011 ses a ratio of EPAz‘DHA of 1:1 to 1:30 or 1:1 to 1:3 by weight of total omega-3 polyunsaturated fatty acids.

In some embodiments, the microbial oil comprises a ratio of EPA:DHA of 1:1 to 122.5 by weight of total omega-3 polyunsaturated fatty acids.

In another embodiment, the microbial oil comprises a ratio of EPA:DHA of 1 :4 to 1:7 by weight of total omega-3 polyunsaturated fatty acids.

In some embodiments, the ial oil comprises a ratio of EPAzDHA of at least of total 1:1, at least 1:1.5, at least 1:2, at least 122.5, at least 1:3, or at least 1:4 by weight omega-3 polyunsaturated fatty acids. Useful ranges can be selected between any of these values, for example, a ratio of A of 1:1 to 1:1.5, [:1 to 1:2, 1:15 to 1:2, 1:1 to 1:2.5, 1:2 to 122.5, and 1:4 to 1:7 by weight of total omega-3 polyunsaturated fatty acids.

In yet a further embodiment, the microbial oil is produced by the Schizochytrium The invention is directed to compositions comprising a microorganism of the invention, an isolated biomass of the invention, a microbial oil of the invention, or combinations thereof.

A microorganism, biomass, or microbial oil of the invention can be further chemically or physically d or processed based on the requirements of the composition by any known technique.

Microorganism cells or biomasses can be dried prior to use in a ition by methods including, but not limited to, freeze ; air drying, spray drying, tunnel , vacuum drying (lyophilization), and a similar process. Alternatively, a harvested and washed biomass can be used directly in a composition without drying. See, e.g., US.

Patent Nos. 5,130,242 and 6,812,009, each of which is incorporated by nce herein in its entirety.

Microbial oils of the invention can be used as starting material to more efﬁciently produce a product enriched in a fatty acid such as EPA. For example, the microbial oils of the invention can be subjected to various puriﬁcation techniques known in the art, such as distillation or urea adduction, to produce a higher potency t with higher concentrations of EPA or another fatty acid. The microbial oils of the invention can also be used in al ons to produce compounds derived from fatty acids in the oils, such as esters and salts of EPA or another fatty acid.

A composition of the invention can include one or more excipients- As used , "excipient" refers to a component, or e of components, that is used in a composition of the present invention to give desirable characteristics to the composition, including foods as well as pharmaceutical, cosmetic, and industrial compositions. An ent of the present invention can be described as a "pharmaceutically able" excipient when added to a ceutical composition, meaning that the excipient is a nd, material, composition, salt, and/or dosage form which is, within the scope of sound medical judgment, suitable for contact with tissues of human beings and non- human animals without excessive toxicity, irritation, allergic response, or other problematic complications over the desired duration of contact commensurate with a reasonable beneﬁt/risk ratio. In some embodiments, the term "pharmaceutically acceptable" means approved by a tory agency of the Federal or a state government or listed in the US. Pharmacopeia or other generally recognized international pharmacopeia for use in animals, and more ularly in humans. Various excipients can be used. In some embodiments, the excipient can be, but is not limited to, an alkaline agent, a stabilizer, an antioxidant, an adhesion agent, a separating agent, a coating agent, a surfactant, a an exterior phase component, a controlled-release component, a solvent, humectant, a buffering agent, a ﬁller, an emollient, or combinations thereof. Excipients in addition to those discussed herein can include ents listed in, though not limited Inclusion of an to, Remington: The Science and Practice ofPharmacy, 21St ed. (2005). excipient in a ular classiﬁcation herein (e.g., nt") is intended to rate rather than limit the role of the excipient. A particular excipient can fall within multiple classiﬁcations.

Compositions of the invention include, but are not limited to, food products, pharmaceutical compositions, cosmetics, and industrial compositions.

In some embodiments, the composition is a food product. A food product is any food for non—human animal or human consumption, and includes both solid and liquid compositions. A food product can be an additive to animal or human foods. Foods include, but are not limited to, common foods; liquid products, including milks, beverages, therapeutic drinks, and nutritional drinks; functional foods; supplements; nutraceuticals; infant formulas, including formulas for ture infants; foods for pregnant or nursing women; foods for adults; geriatric foods; and animal foods.

In some embodiments, a microorganism, s, or microbial oil of the invention can be used directly as or included as an additive within one or more of: an oil, shortening, spread, other fatty ingredient, beverage, sauce, dairy-based or soy-based food (such as milk, yogurt, cheese and ice-cream), a baked good, a ional product, e.g., as a nutritional supplement (in capsule or tablet form), a vitamin supplement, a diet supplement, a powdered drink, and a ﬁnished or semi-ﬁnished powdered food product.

In some ments, the nutritional supplement is in the form of a vegetarian capsule that is not formed from and does not contain any components from an animal source.

A partial list of food compositions that can include a ial oil of the invention includes, but is not limited to, soya based products (milks, ice creams, yogurts, drinks, and baked food items creams, spreads, whiteners); soups and soup mixes; doughs, batters, including, for example, ﬁne bakery wares, breakfast s, cakes, Cheesecakes, pies, es, s, bars, breads, rolls, biscuits, mufﬁns, pastries, scones, croutons, crackers, sweet goods, snack cakes, pies, granola/snack bars, and toaster pastries; candy; hard confectionery; chocolate and other confectionery; chewing gum; liquid food products, for example milks, energy drinks, infant a, carbonated drinks, teas, liquid meals, fruit , fruit-based drinks, vegetable-based drinks; multivitamin syrups, meal replacers, medicinal foods, and syrups; powdered beverage mixes; pasta; processed ﬁsh ts; processed meat products; processed poultry products; gravies and sauces; condiments (ketchup, mayonnaise, etc.); vegetable sed spreads; dairy products; semi- yogurt; butters; frozen dairy products; ice creams; frozen desserts; frozen yogurts; solid food products such as baby food; puddings and gelatin desserts; processed and unprocessed cheese; e mixes; food bars including energy bars; wafﬂe mixes; salad dressings; replacement egg mixes; nut and nut-based spreads; salted snacks such as potato chips and other chips or crisps, corn chips, la chips, extruded , popcorn, pretzels, potato , and nuts; and specialty snacks such as dips, dried fruit snacks, meat snacks, pork rinds, health food bars and rice/corn cakes.

In some embodiments, a microbial oil of the invention can be used to supplement infant formula. Infant formula can be supplemented with a microbial oil of the invention alone or in combination with a ally reﬁned oil derived from an arachidonic acid (ARA)-producing microorganism. An oducing microorganism, for example, is Mortierella alpina or_Mortierella sect. schmuckeri. Alternatively, infant formulas can be supplemented with a microbial oil of the invention in ation with an oil rich in ARA, including ARASCO® (Martek Biosciences, Columbia, MD).

In some embodiments, the composition is an animal feed. An "animal" includes non-human organisms belonging to the kingdom Animalia, and includes, without limitation, aquatic animals and terrestrial animals. The term "animal feed" or "animal food" refers to any food ed for non—human animals, whether for ﬁsh; commercial ﬁsh; ornamental ﬁsh; ﬁsh ; bivalves; mollusks; crustaceans; shellﬁsh; shrimp; larval shrimp; artemia; rotifers; brine shrimp; ﬁlter feeders; amphibians; reptiles; mammals; ic animals; farm s; zoo s; sport animals; ng stock; racing animals; show animals; heirloom animals; rare or endangered s; companion animals; pet animals such as dogs, cats, guinea pigs, rabbits, rats, mice, or horses; primates such as monkeys (e.g., cebus, rhesus, African green, patas, cynomolgus, and cercopithecus), canids such as apes, orangutans, baboons, gibbons, and nzees; dogs and wolves; felids such as cats, lions, and tigers; equids such as horses, s, and zebras; food animals such as cows, cattle, pigs, and sheep; ungulates such as deer and giraffes; or rodents such as mice, rats, hamsters and guinea pigs; and so on. An animal feed includes, but is not limited to, an aquaculture feed, a domestic animal feed including and. combinations pet feed, a zoological animal feed, a work animal feed, a livestock feed, thereof.

In some embodiments, the composition is a feed or feed supplement for any animal whose meat or products are consumed by humans, such as any animal from which meat, or milk is derived for human consumption. When to such animals, eggs, nutrients such as As can be incorporated into the ﬂesh, milk, eggs or other products of such animals to increase their content of these nutrients.

In some ments, the composition is a dried material that can be crumbled to ‘form particles of an appropriate size for consumption by zooplankton, artemia, rotifers, and ﬁlter feeders. In some embodiments, the zooplankton, artemia, or rotifers fed by the composition are in turn fed to ﬁsh larvae, ﬁsh, shellﬁsh, bivalves, or crustaceans.

In some embodiments, the composition is a pharmaceutical compositiOn. Suitable pharmaceutical compositions e, but are not limited to, an anti-inﬂammatory composition, a drug for treatment of coronary héart disease, a drug for treatment of arteriosclerosis, a chemotherapeutic agent, an active excipient, an osteoporosis drug, an anti-depressant, an anti-convulsant, an anti-Helicobacter pylori drug, a drug for treatment of neurodegenerative disease, a drug for treatment of degenerative liver disease, an antibiotic, a cholesterol lowering composition, and a lglycerol lowering composition. In some embodiments, the composition is a medical food. A medical food includes a food that is in a composition to be consumed or administered externally under the supervision of a. physician and that is intended for the speciﬁc dietary management of scientiﬁc a condition, for which distinctive nutritional requirements, based on recognized principles, are established by medical evaluation.

In some embodiments, the microbial oil can be formulated in a dosage form.

Dosage forms can include, but are not limited to, s, capsules, cachets, pellets, pills, powders and granules, and parenteral dosage forms, Which include, but are not d to, solutions, suspensions, emulsions, and dry powders comprising an effective amount of the microbial oil. It is also known in. the art that such formulations can also n pharmaceutically acceptable diluents, ﬁllers, disintegrants, s, lubricants, tants, hydrophobic vehicles, water e vehicles, emulsiﬁers, buffers, humectants, moisturizers, solubilizers, preservatives and the like. Administration forms can include, but are not limited to, tablets, dragees, capsules, caplets, and pills, which contain the microbial oil and one or more suitable pharmaceutically able rs.For oral administration, the microbial oil can be combined with pharmaceutically acceptable carriers well known in the art. Such carriers enable the microbial oils of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ion by a subject to be treated. In some embodiments, the dosage form is a tablet, pill or caplet. Pharmaceutical preparations for oral use can be ed by adding a solid ent, optionally grinding the resulting mixture, and processing the mixture of granules, aﬁer adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include, but are not limited to, ﬁllers such as sugars, including, but not limited to, lactose, sucrose, mannitol, and sorbitol; cellulose preparations such as, but not limited to, maize starch, wheat starch, rice starch, potato starch, gelatin, gum anth, methyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, and nylpyrrolidone (PVP). If desired, disintegrating agents can be added, such as, but not limited to, the cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt f such as sodium alginate.

Pharmaceutical preparations that can be used orally include, but are not limited to, push— ﬁt capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. In some embodiments, the dosage form is a vegetarian dosage form, in which the dosage form is not formed from and does not contain any ents from an animal source. In some embodiments, the vegetarian dosage form is a vegetarian capsule.

In some embodiments the oral dosage form is a vegetarian gel capsule comprising modiﬁed cornstarch, carrageenan, glycerin, sorbitol, puriﬁed water, beta-carotene and . caramel powder.

In some embodiments the oral dosage form is formulated with an oil sed of about 100 mg, about 200 mg, about 300 mg about 400 mg, about 500 mg, about 550mg, or about 600mg of DHA and EPA content per one gram of oil.

In some embodiments the oral dosage form is formulated with an oil comprised of from about 300 mg to about 700 mg of DHA and EPA content per one gram of oil.

In a further embodiment, the oral dosage form is ated with an oil comprised of from about 360mg to‘about 670 mg of DHA and EPA content per one gram of oil.

In some embodiments the gel capsule can be formulated with an oil sed of about 100 mg, about 200 mg, about 300 mg about 400 mg, about 500 mg, about 550mg, of oil. or about 600mg of the total amount of DHA and EPA t per one gram In some embodiments the gel capsule can be formulated with an oil comprised of from about 300 mg to about 700 mg of DHA and EPA content per one gram of oil.

In a further embodiment, the gel capsule can be formulated with an oil sed of from about 360mg to about 670 mg of DHA and EPA content per one gram of oil, In yet a further embodiment, the total amount of DHA and EPA is at least about 400 mg per one gram of oil.

In still yet a further embodiment, the total amount of omega-3 polyunsaturated fatty acids is at least about 400 mg per one gram of oil.

In a still further embodiment, the total amount of DHA and EPA is about 400 mg per one gram of oil.

In an even further embodiment, the total amount of DHA and EPA is at least about 500 mg per one gram of oil.

In an even further embodiment, the total amount of omega-3 polyunsaturated fatty acids is at least about 500 mg per one gram of oil.

In another embodiment, the total amount of DHA and EPA is about 500 mg per one gram of oil.

In some embodiments, the composition is a ic. Cosmetics include, but are not limited to, emulsions, , lotions, masks, soaps, shampoos, ’washes, facial ic agents can creams, conditioners, make-ups, bath agents, and dispersion liquids. be medicinal or dicinal.

In some embodiments, the composition is an rial composition. In some embodiments, the composition is a starting material for one or more manufactures. A manufacture es, but is not limited to, a polymer; a photographic photosensitive material; a detergent; an industrial oil; or an industrial detergent. For example, US.

Patent No. 7,259,006 describes use of DHA-containing fat and oil for production of c acid and tion of photographic sensitive materials using behenic acid.

In some embodiments, the itions can be used in the treatment of a condition in humans or non-human animals. In some embodiments, the compositions can be used for nutrition in humans or non-human animals.

The terms "treat" and "treatment" refer to both therapeutic treatment and prophylactic or preventative es, wherein the object is to prevent or slow down (lessen) an undesired physiological condition, disease, or disorder, or to obtain ial or desired clinical results. For purposes of this invention, beneﬁcial or desired al results include, but are not limited to, alleviation or elimination of the symptoms or signs associated with a condition, disease, or disorder; diminishment of the extent of a condition, disease, or disorder; stabilization of a condition, disease, or disorder, (i.e., where the condition, disease, or disorder is not worsening); delay in onset or progression of the condition, e, or disorder; amelioration of the condition, disease, or disorder; remission (whether partial or total and whether detectable or undetectable) of the condition, disease, or disorder; or ement or improvement of a condition, disease, or disorder. ent includes eliciting aclinically signiﬁcant response without excessive side s. Treatment also includes prolonging al as compared to expected survival if not ing treatment.

In some embodiments, the composition is used to treat a condition, disease, or disorder such as acne, acute inﬂammation, age related maculopathy, allergy, Alzheimer's, arthritis, , atherosclerosis, autoimmune disease, blood lipid er, breast cysts, cachexia, cancer, cardiac restcnosis, cardiovascular diseases, chronic inﬂammation, coronary heart disease, cystic ﬁbrosis, degenerative disorder of the liver, diabetes, eczema, gastrointestinal disorder, heart disease, high triacylglycerol levels, hypertension, hyperactivity, immunological diseases, inhibiting tumor growth, inﬂammatory conditions, intestinal disorders, kidney dysfunction, leukemia, major depression, multiple sclerosis, neurodegenerative disorder, osteoarthritis, osteoporosis, peroxiSomal disorder, preeclampsia, preterm birth, psoriasis, pulmonary disorder toid tis, risk of heart disease, or thrombosis.

In some embodiments, the composition is used to increase the length of gestation of a fetus in the third trimester.

In some ments, the composition is used to control blood re.

In some embodiments, the composition is used to improve or maintain cognitive function.

In some ments, the composition is used to improve or maintain .

In some embodiments, the composition is used to maintain a healthy heart.

The composition or dosage form can be administered into the body of a subject by form. A nce is considered to any route compatible e composition or dosage be "administered" if the substance is introduced into the body of the subject by the subject, or if another person, a machine, or a device introduces the substance into the body of the subject. "Administering," therefore, includes, e.g., self—administration, administration by others, and indirect administration. The term "continuous" or "consecutive," as used herein in reference to "adﬁ1inistration," means that the frequency of stration is at least once daily. .Note, however, that the frequency of administration can be greater than once daily and still be "continuous" or "consecutive," the dosage levels as speciﬁed herein are e.g., twice or even three times daily, as long as not exceeded. The means and methods for stration are known in the art and an artisan can refer to various pharrnacologic references for guidance. For example, "Modern Pharmaceutics," Banker & Rhodes, Informa Healthcare, USA, 4th ed. (2002); and "Goodman & Gilman’s The Pharmaceutical Basis of eutics," McGraw-Hill Companies, Inc., New York, 10th ed. (2001) can be consulted.

By "subject," "individual," or "patient" is meant any subject, whether human or non-human, for whom diagnosis, sis, therapy, or administration of the composition or dosage form is d. Mammalian ts include, but are not limited to, humans; domestic animals; farm animals; 200 animals; sport animals; pet s such as dogs, cats, guinea pigs, rabbits, rats, mice, or horses; primates such as monkeys (e.g., cebus, rhesus, African green, patas, cynomolgus, and cercopithecus), apes, orangutans, bab‘Oon‘s, gibbons, and chimpanzees; canids such as dogs and wolves; felids such as cats, lions, and ; equids such as horses, donkeys, and zebras; food animals such as cows, cattle, pigs, and sheep; ungulates such as deer and giraffes; rodents such as mice, rats, rs and guinea pigs; and so on. The term subject also encompasses model animals, e.g., disease model animals. In some ments, the term subject includes le animals, either economically or otherwise, e.g., economically important breeding stock, racing animals, show animals, heirloom animals, rare or endangered animals, or companion animals. in certain embodiments, the subject is a human subject. In n embodiments, the subject is a non-human subject.

The composition can be administered as a tional amount," "therapeutically effective amount," a "prophylactically effective amount," a "therapeutic dose," or a "prophylactic dose." A "nutritional amount" refers to an amount effective, at dosages and for periods of time ary, to achieve a desired nutritional result. A nutritional result can be, e.g., increased levels of a desirable fatty acid component in a subject. A "therapeutically effective amount" or "therapeutic dose" refers to an amount ive, at dosages and for periods of time necessary, to achieve a desired therapeutic result. A therapeutic result can be, e.g., lessening of symptoms, prolonged survival, improved mobility, and the like. A therapeutic result need not be a "cure." A "prophylactically WO 13211 effective amount" or "prophylactic dose" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in ts prior to or at an earlier stage of disease, a prophylactically effective amount will be- less than a therapeutically effective amount for treatment of an advanced stage of disease.

Various dosage amounts of the composition, dosage form, or pharmaceutical composition can be stered to a subject, based on the amount of EPA or other fatty acid component of the microorganism, biomass, or ial oil to be administered to the subject. The terms "daily dosage," "daily dosage level," and "daily dosage amount" refer herein to the total amount of EPA or other fatty acid component administered per day (per 24 hour period). Thus, for example, administration of EPA to a subject at a daily dosage of 2‘ mg means that the subject receives a total of 2 mg of EPA on a daily basis, whether the EPA is administered as a single dosage form comprising 2 mg EPA, or alternatively, four dosage forms sing 0.5 mg EPA each (for a total of 2 mg EPA). In some - ments, the daily amount of EPA is administered in a single dosage form, or in two dosage forms. The dosage forms of the present invention can be taken in a single application or multiple applications. For example, if four tablets are taken daily, each tablet comprising 0.5 mg EPA, then all four tablets can be taken once daily, or 2 tablets can be taken twice daily, or 1 tablet can be taken every 6 hours. In some embodiments, the daily dosage is about 100 mg to about 15 g of'EPA. In some embodiments, the daily dosage is about 0.5 mg to about 250 mg, about 100 mg to about 250 mg, about 100 mg to about 500 mg, about 100 mg to about 1 g, about 1 g to about 2.5 g, about 1 g to about 5 g, about 1 g to about 10 g, about 1 g to about 15 g, about 5 g to about 10 g, about 5 g to about 15 g, about 10 g to about 15 g, about 100 mg to about 10 g, about 100 mg to about g, or about 100 mg to about 2.5 g of EPA, DHA, or a combination f. In some embodiments, the composition is a dosage form that comprises about 0.5 mg to about 250 about 100 mg to about 500 mg, 100 mg to about 250 mg, about 0.5 mg to about 500 mg, mg, about 0.5 mg to about] g, or about 100 mg to about 1 g of EPA, DHA, or a combination thereof per dosage form.

Administration of the compositions or dosage forms of the present invention can be ed using various regimens. For example, in some embodiments, administration -4]- occurs daily on utive days, or alternatively, occurs every other day (bi-daily).

Administration can occur on one or more days.

Administration of the compositions and dosage forms can be combined with other regimens used for treatment? of the condition. For example, the method of the t invention can be combined with diet regimens (e.g., low carbohydrate diets, high protein diets, high ﬁber diets, etc.), exercise regimens, weight loss regimens, smoking cessation regimens, or ations thereof. The method of the present invention can also be used in combination with other pharmaceutical products in the treatment of the condition. The compositions or dosage forms of the present invention can be administered before or aﬁer other regimens or pharmaceutical products. [01411 The invention is directed to kits or packages ning one or more units of a composition of the invention. Kits or packages can include units of a food product, phamiaceutical composition, cosmetic, or industrial composition comprising the microorganism, biomass, or microbial oil of the ion, or combinations f. Kits or packages can also include an ve comprising the microorganism, biomass, or microbial oil of the invention, or combinations thereof for preparation of a food, cosmetic, pharmaceutical ition, or industrial composition.

In some ments, the kit or package contains one or more units of a pharmaceutical composition to be administered according to the methods of the present invention. The kit or package can contain one dosage unit, or more than one dosage unit (i.e., multiple dosage units). If multiple dosage units are present in the kit or e, the multiple dosage units can be optionally arranged for sequential administration.

The kits of the present invention can optionally contain ctions associated with the units or dosage forms of the kits. Such instructions can be in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceutical products, which notice reﬂects approval by the agency of the manufacture, use or sale for human administration to treat a condition or disorder. The instructions can be in any form which conveys information on the use of the units or dosage forms in the kit according to the methods of the invention. For example, the instructions can be in the form of printed matter, or in the form of a pre-recorded media device.

In the course of ation of a patient, a medical professional can determine that administration of one of the methods of the present ion is appropriate for the 2012/047731 patient, or the physician can determine that the patient's condition can be improved by administration of one of the‘ methods of the present invention. Prior to prescribing any regimen, the physician can counsel the patient, for example, on the various risks and s associated with the regimen. The patient can be provided full disclosure of all known and suspected risks associated with the regimen. Such counseling can be ed verbally, as well as in n form. In some embodiments, the ian can provide the patient with literature materials on the regimen, such as product ation, educational ‘ materials, and the like.

The present invention is directed to s of educating consumers about the s of treatment, the method comprising distributing the dosage forms with consumer information at a point of sale. In some embodiments, the distribution will occur at a point of sale having a pharmacist or healthcare er.

The term "consumer information" can include, but is not limited to, an English language text, non-English language text, visual image, chart, telephone recording, e, and access to a live customer service representative. In some embodiments, to the consumer information will provide directions for use of the dosage forms according methods of the present invention, appropriate age use, indication, contraindications, appropriate dosing, warnings, telephone number or e address. In some embodiments, the method further comprises providing professional information to relevant persons in a position to answer er questions regarding use of the disclosed regimens according to the methods of the present invention. The term "professional information" includes, but is not limited to, information concerning the regimen when administered according to the methods of the present invention that is designed to enable a l professional to answer costumer questions.

A "medical professional," includes, for example, a physician, physician assistant, nurse, nurse tioner, pharmacist and customer service representative.

Having generally bed this invention, a further understanding can be obtained by reference to the examples provided herein. These examples are for purposes of illustration only and are not intended to be limiting.

EXAMPLE 1 Isolation of Microorganisms Samples were collected from intertidal habitats during low tide, including bays and estuaries along the West Coast of North a (Califomia, Oregon, and gton) and Hawaii. Water, sediment, living plant material, and decaying plant/animal debris were placed into sterile 50 ml tubes. Portions of each sample along with the water were spread onto solid agar plates of isolation media. Isolation media consisted of: 500 ml of artificial seawater, 500 ml of distilled water, 1 g of glucose, 1 g of glycerol, 13 g of agar, l g of glutamate, 0.5 g of yeast extract, 0.5 g casein hydrolysate, 1 ml ofa vitamin solution (100 mg/L thiamine, 0.5 mg/L biotin, 0.5 mg 8.2), 1 ml ofa trace mineral solution (PII metals, ning per liter: 6.0 g FeC136H20, 6.84 g H3BO3, 0.86 g MnClz4H20, 0.06 g ZnClz, 0.026 CoC126HzO, 0.052 g NiSO4H20, 0.002 g CuSO45H20 and 0.005 g Na2M0042H20), and 500 mg each of llin G and streptomycin sulfate.

The agar plates were incubated in the dark at 20-25°C. After 2-4 days the agar plates were examined under cation, and colonies of cells were picked with a e toothpick and restreaked onto a fresh plate of media. Cells were repeatedly streaked onto fresh media until contaminated organisms were removed. Two of the isolated microorganisms were deposited under ATCC Accession Nos. PTA-10212 and PTA- 10208.

Taxonomic Characteristics of the Isolated Microorganism Deposited Under ATCC Accession No. PTA-10212 {0150] Cultures of the isolated microorganism deposited under ATCC Accession No.

PTA-10212 ("PTA-10212") appeared as white, wet, smeared colonieswithout e isolated sori.

PTA—10212 was grown on solid and liquid FFM, solid KMV, KMV slush (1%), KMV broth, and MH broth to further examine growth characteristics. PTA-10212 was ed to grow rapidly on KMV and MH. See, e.g., Porter D., 1989. Phylum Labyrinthulomycota. In Margulis, L., Corliss, J.O., Melkonian, M., Chapman, D.J. (Eds) Handbook of Protoctista, Jones and Bartlett, , pp. 388-398 (KMV); Honda et al., Mycol. Res. 102:439-448 (1998) (MH); and US. Patent No. 5,130,242 (FFM), each of which is incorporated herein by reference in its ty.

The following observations were made after growth of PTA-10212 over several days on solid FFM media, aﬁer 72 hours growth in KMV medias, and MH broth.

Sporangia were not clumped in/on any media and were very small (5-10 um). PTA- 10212 did not demonstrate the copious tetrads characteristic of Schizochytrium cleavage ns. Amoeboid cells appeared about 24 hours after transfer to fresh solid media.

These amoeboid cells were gone aﬁer a few days and were not evident in liquid or slush media. Unlike iochytrium, bed by Yokoyama, R. et al., ience 48(6): 329-341 (2007), as having the appearance of "small ains on the bottom of the ﬂask" when grown in liquid media, PTA-10212 did not settle at the bottom of the ﬂask but was suspended in both KMV and MH liquid media. The sporangia were not as dense as l of Schizochytrium or Oligochytrium, which ‘also have robust ectoplasmic networks that were absent from PTA-10212. While most s undergo vegetative ge of small sporangia or assimilative cells by the division of a larger sporangium several hours, PTA-10212 formed dumbbell-shaped elongated assimilative over cells, which then formed a thin isthmus that pulled apart as the ends of the dumbbell separated.

The resulting cells appeared to be small assimilative cells. Direct transformation of an amoebdid cell into the dumbbell shaped assimilative cell was not observed. Typical biﬂagellate zoospores were ed swimming but were relatively rare. PTA—10212 was non-proliﬁc, dividing by vegetative cleavage. Direct release of zoospores was not observed, gh 2003pores were observed swimming. Vegetative cells were very small (2 pm to 5 pm).

PTA-10212 was further examined using the ﬂow-through technique, in which microscopic slides were prepared by suspending a small portion of an agar-grown colony in a drop of half-strength sea water. With this technique, y sporangia were observed to be globose and approximately 10 pm in er. Walls were very thin and remnants were not observed when binary division of the protoplast was initiated.

Repeated binary division produced 8-16 smaller (4-5 pm in diameter) secondary sporangia. The secondary sporangia remained ent for several hours before again releasing an amorphous protoplast. The amorphous protoplast divided by pinching and pulling, initially producing typical dumbbell-shaped intermediate stages and ﬁnally resulting in 4-8 small globose bodies 2.5-2.8 pm in diameter. The latter rested for several minutes up to 1-2 hours, then changed shape (elongated) and turned into biﬂagellate zoospores, 2.3-2.5 x 3.7-3.9 um. Zoospores were abundant and could be precisely ed when they came to rest. Zoospores then rounded off and started a new cycle of _45_ development. The zoospores were larger than Sicyoidochytrium minutum and smaller than Ulkem’a visurgensis.

PTA-10212 was further terized based 0n the similarity of its 183 rRNA gene to that of known species. Genomic DNA was ed from PTA-10212 by standard procedures. See, for example, Sambrook J. and Russell D. 2001. lar cloning: A laboratory , 3rd edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. Brieﬂy: (1) 500 uL of cells were centrifuged from mid-log culture. The cells were re-centrifuged, and all traces of liquid were removed from the cell pellet with a small-bore tip; (2) pellets were resuspended with 200 uL lysis buffer (20 mM Tris pH 8.0, 125 ug/mL Proteinase K, 50 mM NaCl, 10 mM EDTA pH 8.0, 0.5% SDS); (3) cells were lysed at 50°C for 1 hour; (4) the lysis mixture was pipetted into lock gel (PLG-Eppendort) 2 mL tubes; (5) equal volume of P:C:I was added and allowed to mix for 1.5 hours; (6) the tubes were centrifuged at 12,000 x g for 5 minutes; (7) the aqueous phase was removed from above the gel within the PLG tube and an equal volume of chloroform was added to the s phase, and mixed for 30 minutes; (8) the tubes were centrifuged at 14,000 x g for approximately 5 minutes; (9) the top layer (aqueous phase) was pipetted away from the chloroform, and placed in a new tube; (10) 0.1 volume of 3 M NaOAC was added and mixed (inverted several times); (11) 2 s of 100% EtOH were added and mixed (inverted several times) with genomic DNA precipitant g at this stage; (12) the tubes were centrifuged at 4°C in a microcentrifuge at 14,000 x g for approximately 15 minutes; (13) the liquid was gently poured off with genomic DNA remaining at the bottom of the tube; (14) the pellet was washed with 0.5 mL 70% EtOH; (15) the tubes were centrifuged at 4°C in a microcentrifuge at 14,000 x g for approximately 5 minutes; (16) the ’EtOH was gently poured off and the genomic DNA pellet was dried; and (17) a suitable volume of H20 and RNase was added directly to the genomic DNA pellet. The PCR ampliﬁcation of the 18s rRNA gene was carried out with primers previously described (Honda er. al., J. Euk.

Micro. 46(6): 637-647 (1999). The PCR ions with chromosomal DNA template were as follows: 0.2 uM dNTPs, 0.1 uM each primer, 8% DMSO, 200 ng chromosomal DNA, 2.5 U Herculase® 11 Fusion DNA Polymerase (Stratagene), and Herculase® buffer (Stratagene) in a 50 uL total volume. The PCR Protocol included the following steps: (1) 95°C for 2 s; (2) 95°C for 35 seconds; (3) 55°C for 35 seconds; (4) 72°C for l minute and 30 seconds; (5) repeat steps 2-4 for 30 cycles; (6) 72°C for 5 minutes; and (7) hold at 4°C. .

PCR ampliﬁcation yielded a distinct DNA product with the expected size using chromosomal template described above. The PCR product was cloned into the vector pJET1.2/blunt (Fermentas) according to the manufacturer's instructions, and the insert sequence was determined using supplied standard s.

Phylogenetic analysis places PTA-10212 within the lineage that includes Thraustochytrium pachydermum and Thraustochytrium atum with moderate support. The sporangia of T. pachydermum have very thick cell walls. T. aggregatum forms clearly visible clumps of sori that are . PTA-10212 shows neither of these characteristics. The presence of many arnoeboid cells has been described in other taxa, such as Ulkenia, T. gaertnerium, A. limiacinum, and S. mangrovei; however, the ptionsassociated with those taxa differ from the observed characteristics of the e. Moreover, PTA-10212 did not show phylogenetic'afﬁnity towards any of these taxa. [0l57] Table 3 shows a comparison of the 188 rRNA ce from the rganism . deposited under ATCC Accession No. PTA-10212 to DNA ces in the National Center for Biotechnology Information (NCBI) electronic database. The percent identity was determined using two different calculations. "Calculation #1" takes into consideration any "gaps" that occur in the sequences, either from non-homologous regions or partial sequence -VectorNTI default settings). lation #2" does not include calculated penalties for gaps (Alian-VectorNTI "IDENTITY" matrix Table 3: Comparison of 183 rRNA Sequences Thraustochytrids % Identity % Identity Calculation #1 Calculation #2 Thraustoch trium pachydermum 93% Thrausloch Irium a,; eatum . 92% Thraustoch trium aertnerium 92% Ulkenia visur ensis 82% 92% Schizoch trium s. PTA-9695 80% 92% Schizoch Irium man rovei 80% 91% Schizoch trium s. ATCC 20888 80% Aurantioch trium limiacinum 79% (p): indicates partial sequence As shown in Table 3, it was found that, in terms of % ty, the 18s rRNA gene ATCC Accession No. ce (SEQ ID NO:1) from the microorganism deposited under PTA-10212 is related, though not identical, to 185 rRNA gene sequences available in the NCBI database. It is generally recognized that organisms can have closely related 185 rRNA gene ces while belonging to a different genus or species.

Based on the above characterization, the ed microorganism deposited under ATCC Accession, No. PTA-10212 is believed to represent a new Thraustochytrium species and is therefore also designated as Thrauslochytrium Sp. ATCC PTA-10212.

Taxonomic teristics of the Isolated Microorganism Deposited Under ATCC Accession No. PTA-10208 The microorganism deposited under ATCC Accession No. PTA-10208 ("PTA- 10208") was identiﬁed as a olate (an individual cell isolated from a culture and maintained as a new te and ct culture) of the microorganism deposited under ATCC Accession No. PTA-9695 ("PTA-9695"), described in US. Appl. No. ,687 ‘ and , each of which is orated herein by reference in its entirety.

PTA-10208 sharestaxonomic characteristics with PTA-9695. PTA-9695 was found to have biﬂagellate at discharge that swim actively away ﬁom the zoospores mature sporangium, wall remnants of which were y visible (in phase contrast) after spore release. PTA-9695 sporangia measured 12.5 um to 25 pm in diameter, There were 8 to 24 spores zoospores were 2.5 pm to 2.8 pm x 4.5 pm to 4.8 pm in size. per individual PTA-9695 sporangium. Settled PTA-9695 zoospores enlarged and rapidly - Underwent binary divisions leading to tetrads, octads, and ﬁnally to clusters of sporangia.

Tetrad formation commenced at a very early stage prior to maturity of the sporangia.

These characteristics are in agreement with the genus Schizochytrium. In terms of % identity, the PTA—9695 185 rRNA gene sequence (SEQ ID NO:2), which is shared by PTA-10208, was found to be closely d, though not identical, to the 18s rRNA gene Micro. 46(6): 7 sequence of T. aggregatum provided in Honda, D. et al., J. Euk. (1999). The 18s rRNA sequence published for Thraustochytrium aggregatum is a partial in the middle of the sequence. sequence, with an approximately 71 DNA nucleotide gap PTA-9695 is believed to ent a new Schizochytrium species. As such, the sub- isolate PTA-10208 is also designated as Schizochytrium Sp. ATCC PTA-10208.

EXAMPLE2 Growth Characteristics of the Isolated Microorganism Deposited Under ATCC Accession No. PTA-10212 The isolated microorganism deposited under ATCC Accession No. PTA-10212 was examined for growth characteristics in individual fermentation runs, as described below. Typical media and ation conditions are shown in Table l.

In carbon (glycerol) and nitrogen-fed cultures with 1000 ppm Cl' at 225°C with % dissolved oxygen at pH 7.3, PTA-10212 produced a dry cell weight of 26.2 g/L after 138 hours of culture in a 10 L fermentor volume. The lipid yield was 7.9 g/L; the omega- 3 yield was 5.3 g/L; the EPA yield was 3.3 g/L; and the DHA yield was 1.8 g/L. The fatty acid t was 30.3% by weight; the EPA t was 41.4% of fatty acid methyl esters (FAME); and the DHA content was 26.2% of FAME. The lipid productivity was 1.38 g/L/day, and the omega-3 tivity was 0.92 g/L/day under these conditions, with 0.57 g/L/day EPA productivity and 0.31 g/L/day DHA productivity.

In carbon (glycerol) and nitrogen-fed cultures with 1000 ppm Cl' at 225°C with % dissolved oxygen at pH 7.3, PTA-10212 produced a dry cell weight of 38.4 g/L after 189 hours of culture in a 10 L fermentor . The lipid yield was 18 g/L; the omega- 3 yield was 12 g/L; the EPA yield was 5 g/L; and the DHA yield was 6.8 g/L. The fatty acid t was 45% by weight; the EPA content was 27.8% of FAME; and the DHA content was 37.9% of FAME. The lipid productivity was 2.3 g/L/day, and the omega-3. productivity was 1.5 g/L/day under these conditions, with 0.63 g/L/day EPA tivity and 0.86 g/L/day DHA productivity.

In carbon (glycerol) and nitrogen-fed cultures with 1000 ppm Cl' at 225°C with % dissolved oxygen at .pH 6.8-7.7, PTA-10212 produced a dry cell weight of 13 g/L after 189 hours of culture in a 10 L fermentor volume. The lipid yield was 5.6 g/L; the omega—3 yield was 3.5 g/L; the EPA yield was 1.55 g/L; and the DHA yield was 1.9 g/L.

The fatty acid t was 38% by weight; the EPA content was 29.5% of FAME; and the DHA content was 36% of FAME. The lipid productivity was 0.67 g/L/day, and the omega-3 tivity was 0.4 g/L/day under these conditions, with 0.20 g/L/day EPA productivity and 0.24 g/L/day DHA productivity. .49- In carbon (glycerol) and nitrogen-fed cultures with 1000 ppm Cl' at 22.5-28.5°C with 20% dissolved oxygen at pH 6.6-7.2, 212 produced a dry cell weight of 36.7 g/L —l 48.7 g/L after 191 hours of culture in a 10 L ferrnentor volume. The lipid yield was .2 g/L — 25.3 g/L; the omega-3 yield was 9.3 g/L - 13.8 g/L; the EPA yield was 2.5 g/L — 3.3 g/L; and the DHA yield was 5.8 g/L 1 1 g/L. The fatty acid content was 42.4% 53% by weight; the EPA t. was 9.8% - 22% of FAME; and the DHA content was 38.1% - 43.6% of FAME. The lipid productivity was 1.9 g/L/day — 3.2 g/L/day, and the omega-3 productivity was 1.2 g/L/day - 1.7 g/L/day under these conditions, with 0.31 y — a 0.41 g/L/day EPA productivity and 0.72 g/L/day 1.4 g/L/day DHA productivity.

Growth Characteristics of the Isolated Microorganism ted Under ATCC Accession No. PTA-10208 The isolated microorganism deposited under ATCC Accession No. PTA-10208 was examined for growth characteristics in individual fermentation runs, as described below. Typical media and ation conditions are shown in Table 2.

In carbon (glucose) and nitrogen-fed cultures with 1000 ppm Cl' at 225°C at pH 7.0 with 20% dissolved oxygen during the nitrogen feed and- 10% dissolved oxygen thereafter, PTA-10208 produced a dry cell weight of 95 g/L after 200 hours of culture in a L fer-mentor volume. The lipid yield was 53.7 g/L; the omega-3 yield was 37 g/L; the EPA yield was 14.3 g/L; and the DHA yield was 21 g/L. The fatty acid content was 57% by weight; the EPA content was 27.7% of FAME; and the DHA content was 39.1% of FAME. The lipid productivity was 6.4 g/L/day, and the 3 productivity was 4.4 g/L/day under these conditions, with 1.7 g/L/day EPA productivity and 2.5 g/L/day DHA productivity.

In carbon (glucose) and nitrogen-fed es with 1000' ppm Cl' at 225°C at pH 7.5 with 20%tdissolved oxygen during the en feed and 10% dissolved oxygen thereafter, PTA—10208 produced a dry cell weight of 56 g/L after 139 hours of culture in a L fermentor volume. The lipid yield was 53 g/L; the omega-3 yield was 34 g/L; the EPA yield was 11.5 g/L; and the DHA yield was 22 g/L. The fatty acid content was 58% by weight; the EPA t was 21.7% of FAME; and the DHA content was 41.7% of FAME. The lipid productivity was 9.2 g/L/day, and the omega-3 productivity was 5.9 g/L/day under these ions, with 2 y EPA productivity and 3.8 g/L/day DHA productivity.

In carbon (glucose) and nitrogen-fed cultures with 1000 ppm Cl' at 225°C at pH 7.0 with 20% dissolved oxygen during the nitrogen feed and 10% dissolved oxygen thereafter, PTA-10208 produced a dry cell weight of 93.8 g/L after 167 hours of culture in a 2000 L fermentor volume. The lipid yield was 47.2 g/L; the omega-3 yield was 33.1 g/L; the EPA yield was 10.5 g/L; and the DHA yield was 20.4 g/L. The fatty acid content was 50.6% by weight; the EPA content was 23% of FAME; and the DHA t was 42.6% of FAME. The lipid productivity was 6.8 g/L/day, and the omega-3 productivity was 4.7 g/L/day under these conditions, with 1.5 g/L/day EPA productivity and 2.9 g/L/day DHA productivity.

In carbon (glucose) and nitrogen—fed cultures with 1000 ppm Cl' at 225°C at pH 7.0 with 20% dissolved oxygen during the nitrogen feed and 10% dissolved oxygen thereafter, PTA-10208 produced a dry cell weight of 105 g/L after 168 hours 'of culture in a 2000 L fermentor volume. The lipid yield was 46.4g/L; the omega-3 yield was 33 g/L; the EPA yield was 10.7 g/L; and the DHA yield was 20.3 g/L. The fatty acid content was 43.9% by weight; the EPA content was 24% of FAME; and the DHA contentwas 43.7% of FAME. The lipid productivity was 6.6 y, and the omega—3 productivity was 4.7 g/L/day under these conditions, with 1.5 g/L/day EPA productivity and 2.9 g/L/day DHA tivity.

In carbon (glucose) and nitrogen-fed cultures with 1000 ppm Cl' at 225°C at pH 7.0 with 20% dissolved oxygen during the nitrogen feed and 10% dissolved oxygen thereafter, PTA-10208 ed a dry cell weight of 64.8 g/L aﬁcr 168 hours of culture in a 2000 L fermentor volume. The lipid yield was 38.7 g/L; the omega-3 yield was 29.9 g/L; the EPA yield was 8.5 g/L; and the DHA yield was 16.7 g/L. The fatty acid content was 59.6% by weight; the EPA content was 23% of FAME; and the DHA content was 42.3% of FAME. The lipid productivity was 5.53 g/L/day, and the omega-3 productivity was 3.8 g/L/day under these conditions, with 1.2 g/L/day EPA productivity and 2.3 y DHA productivity.

Fatty Acid Proﬁles of Microorganism Strains ATCC PTA-10208 and PTA-10212 Four samples of biomass 0208 Sample #1; PTA-10208 Sample #2; PTA- 10212 Sample #1; and 212 Sample #2) were analyzed for total crude oil content by solvent extraction, lipid classes were determined by high performance liquid chromatography/evaporative light scattering ion (HPLC/ELSD), triacylglycerol (TAG) were analyzed by ass spectrometry (HPLC/MS), and fatty acid (FA) proﬁles were determined by gas chromatography with ﬂame tion detection (GC- FID). The crude lipid content of each freeze dried s was determined using solvent ng with hexane and compared to the sum of FAME (mg/g) generated by direct steriﬁcation, and the resultant fatty acid methyl esters (FAME) were quantiﬁed by GC/FID analysis. Fatty acids in the ted crude lipid were also quantiﬁed by transesteriﬁcation and quantiﬁed using GC/FID analysis of the resultant FAME. The weight percent of all neutral lipids (NL) and free fatty acids (FFA) were determined in the extracted crude lipid using'norrnal phase HPLC with ELSD and atmospheric pressure chemical ionization-MS (APCI-MS) identiﬁcation. The method separates and quantiﬁes sterol esters (SE), TAG, free fatty acids (FFA);1,3-diacylglycerols (1,3-DAG), sterols, 1,2-diacylglycerols (1,2—DAG), and monoacylglycerols (MAG). Results are shown in Tables 4 and 5, below.

TAG and phospholipids (PL) were isolated from the crude oils extracted from the four samples of s (PTA-10208 Sample #1; PTA-10208 Sample #2; PTA-10212 Sample #1; and PTA-10212 Sample #2). TAG was isolated using low pressure ﬂash chromatography and PL was ed ’using solid phase extraction (SPE). The identity of each isolated fraction was conﬁrmed by thin layer chromatography (TLC). The fatty acid proﬁles of the isolated TAG and PL fractions were determined following direct transesteriﬁcation using GC-FID as FAME. Results are shown in Tables 6 and 7, below.

The total crude oil content and fatty acid proﬁles :of isolated lipid classes were also determined for two additional samples of biomass from microorganism strain ATCC PTA-10212 (PTA-10212 Sample #3 and PTA-10212 Sample #4). Crude oil was obtained from each sample by hexane extraction, and individual lipid classes were isolated using low re ﬂash chromatography. The fatty acid s of the biomass, crude oil, and isolated fractions were determined using GC-FID as FAME. Results are shown in Tables 8-1], below.

Individual lipid classes were isolated from a sample of crude oil from microorganism strain ATCC PTA-10212 (PTA-10212 Sample #5) previously extracted 2012/047731 _52- using the FRIOLEX® s, and the fatty acid proﬁles of each class were determined using GC-FID as FAME. Results are shown in Tables 12 and 13, below.

Individual lipid classes were isolated from a sample of crude oil from microorganism strain ATCC PTA-10208 (PTA-10208 Sample #3) using normal HPLC with ELSD and S identiﬁcation.

Experimental Procedures [01781 Crude Oil Extraction — Crude oil was extracted from samples of freeze-dried s using solvent grinding. For example, approximately 3 grams of biomass was d into a Swedish tube. Three ball bearings and 30 mL of hexane were added to the Swedish tube, which was sealed with a neoprene stopper and placed in a shaker for 2 hours. The resultant slurry was ﬁltered using a Buchner funnel and Whatman ﬁlter paper.

The ﬁltered liquid was collected, the solvent removed under , and the amount of remaining crude lipid determined gravimetrically.

Fatty Acid Analysis — The samples of biomass, extracted crude lipid, and isolated lipid classes were analyzed for fatty acid composition as FAME. Brieﬂy, freeze-dried biomass and isolated lipid classes were weighed directly into a screw cap test tubes, while» samples of the crude oil were dissolved in hexane to give a concentration of' approximately 2 mg/mL. Toluene, containing internal standard, and 1.5 N HCl in methanol was added to each. tube. The tubes were vortexed, then capped and heated to 100°. C for 2 hours. The tubes were allowed to cool, and saturated NaCl in water was added. The tubes were vortexed again and fuged to allow the layers to separate. A portion of the organic layer was then placed in a GC vial and analyzed by GC-FID.

FAME was ﬁed using a 3-point calibration curve generated using Nu—Check-Prep GLC nce Standard (NuCheck, Elysian, MN). Fatty acids present in the extract were expressed as mg/g and as a weight t. Fat content in the samples was estimated assuming equal response to the internal standard when analyzed by GC-FID.

HPLC/ELSD/MS Method — Instrument Agilent 1100 HPLC, Alltech 3300 ELSD, Agilent 1100 Column Phenomenex Luna Silica, 250 x 4.6 mm, pm particle size w/ Guard Column Mobile Phase A — 99.5% Hexanes (Omnisolv) 0.4% Isopropyl alcohol (Omnisolv) 0.1% Acetic Acid B - 99.9% Ethanol (Omnisolv, 95:5 l:IPA) 0.1% Acetic Acid Column Temp. 30°C Flow Rate 1.5 mL/min Injection Volume 5 p.L ELSD Detection Temperature 35°C, Gas ﬂow 1.2 L/min MSD Mass Range 200 — 1200, ntor 225 V Drying Gas Temperature 350°C Vaporizer Temperature 325°C 3500 V .~ Capillary Voltage Corona Current 10 pA Solid Phase Extraction —PL ons were separated from the crude lipid by solid phase extraction (SPE) using 2 g aminopropyl cartridges (Biotage, Uppsala, Sweden) placed in a Vac Elut apparatus (Varian Inc, Palo Alto, USA). The cartridge was conditioned with 15 mL of hexane, and ~60 mg of each sample was dissolved in 1 mL CHC13 and applied to the cartridge. The column was washed with 15 mL of 2:1 CHC13:isopropy1 alcohol to elute all the neutral lipids, which was discarded. The fatty acids were then eluted with 15 mL of 2% acetic acid (HOAc) in ether, which was discarded. The PL portion was eluted with 15 mL of 6:1 MethanolzChloroform, which was collected, dried under en, and weighed.

Flash Chromatography — Flash tography was used to separate the lipid classes present in the crude oil. Approximately 200 mg of crude oil dissolved in hexane Silica Gel was injected onto the head of the column. The chromatography system utilized 60 (EMD Chemical, Gibbstown, NJ) with mobile phase composed of Petroleum Ether and Ethyl Acetate at 5 mL/min (Tables 6-7) or 3 mL/min (Tables 8-13). A step gradient was used to selectively elute each lipid class from the column. The mobile phase gradient d from 100% petroleum ether and ﬁnished with 50% ethyl acetate. Fractions were 2012/047731 ted in 10 mL test tubes using a Gilson FC 204 large-bed fraction collector (Gilson, Inc., Middleton, WI). Each tube was analyzed by thin layer chromatography (TLC) and the tubes containing individual lipid classes (as judged by single spots on TLC plate with expected retention factor (R0) were pooled, concentrated to s, and weighed. The total fraction content was then determined gravimetrically.

TLC Analysis — Thin layer chromatography was conducted on silica gel plates.

The plates were eluted using a solvent system consisting of petroleum ether : ethyl ether : acetic acid (80:20:l) and were visualized using iodine vapor. The Rf values of each spot were then ed with reported literature values for each lipid class.

Analysis of TAG and PL fractions —- The isolated TAG and PL fractions were analyzed for fatty. acid composition as fatty acid methyl esters (FAME). The TAG fractions were dissolved in hexane to give a concentration of approximately 1-2 QOL. 1 mL aliquots of the solutions were concentrated to dryness under en. Toluene, containing internal standard, and 1.5 N HC] in methanol was added to each tube. The tubes were vortexed, then capped and heated to 100° C for 2 hours. Internal standard and HCl ol were added directly to the tubes containing the PL fraction and heated.

The tubes were allowed to cool, and saturated NaCl in water was added. The tubes were ed again and centrifuged to allow the layers to separate. A n of the organic layer was then placed in a GC vial and analyzed by GC-FID. FAMEs were quantiﬁed using a 3—point calibration curve generated using Nu-Check-Prep GLC 502B Reference Standard (NuCheck, Elysian, MN). Fatty acids t in the extract were sed as mg/g and as a % of FAME.

Results PTA-10208 Sample #1 The fatty acid proﬁle of the biomass and extracted crude lipid for PTA-10208 Sample #1 was determined using GC/FID. Fatty acids in the biomass were transesteriﬁed in situ by weighing 28.6 mg of biomass directly into a FAME tube, while a sample of the extracted crude lipid was prepared by weighing 55.0 mg of crude lipid into a 50 mL volumetric ﬂask and transferring 1 ml to a separate FAME tube. The estimated crude lipid content of the biomass was determined to be 53.2% (as SUM of FAME) using GC with FID detection, while 52.0% (wt/wt) lipid was ted from the dry biomass, giving a 97.8% recovery of total lipid. The crude lipid was determined to be 91.9% fatty acids (as SUM of FAME) using GC/FID. The major fatty acids ned in the crude lipid‘ were C16:0 (182.5 mg/g), C20:5 n-3 (186.8 mg/g), and C22:6 n-3 (423.1 mg/g).

The lipid class proﬁle of the extracted crude lipid was determined by weighing 55.0 mg of crude lipid into a 50 mL volumetric ﬂask and transferring an aliquot into an HPLC vial for HPLC/ELSD/MS analysis. According to the HPLC/ELSD/MS analysis, the crude lipid contained 0.2% sterol esters (SE), 95.1% TAG, 0.4% sterols, and 0.5% 1,2-diacylglycerol (DAG). 5% of the TAG fraction ed a peak that eluted directly after the TAG peak, but did not give a recognizable mass Spectrum.

Isolated TAG from this sample as determined by ﬂash chromatography made up approximately 92.4% of the crude oil. PL was not detected by weight or TLC after SPE isolation. The major fatty acids (>50 mg/g) ned in the TAG were Cl6:0 (189 mg/g), C2015 n-3 (197 mg/g), and C22:6 n-3 (441 mg/g).

PTA-10208 Sample #2 The fatty acid proﬁle of the biomass and extracted crude lipid for PTA-10208 Sample #2 was determined using GC/FID. Fatty acids in the s were transesteriﬁed in situ by weighing 32.0 mg of biomass directly into a FAME tube, while a sample of the. extracted crude lipid was prepared by weighing 60.1 mg of crude lipid into a 50 mL volumetric ﬂask and transferring 1 ml to a separate FAME tube. The estimated crude lipid content of the biomass was determined to be 52.4% (as SUM of FAME) using GC with FID detection, while 48.0% (wt/wt) lipid was ted from the dry biomass, giving a 91.7% recovery of total lipid. The crude lipid was ined to be 95.3% fatty acids (as SUM of FAME) using GC/FID. The major fatty acids contained in the crude lipid were Cl6:0 (217.5 mg/g), C2025 n-3 (169.3 mg/g), and C22:6 n-3 (444.1 mg/g).

The lipid class proﬁle of the extracted crude lipid was ined by ng 60.1 mg of crude lipid into a 50 mL volumetric ﬂask and transferring an aliquot into an HPLC vial for HPLC/ELSD/MS analysis. According to the HPLC/ELSD/MS analysis, the crude lipid contained 0.2% SE, 95.7% TAG, 0.3% sterols, and 0.7% 1,2-DAG. 5.1% of the TAG fraction included a peak that eluted directly after the TAG peak, but did not give a recognizable mass spectrum. _ Isolated TAG from this sample made up approximately 93.9% of the crude oil.

PL was not detected by weight or TLC after SPE isolation. The major fatty acids 2012/047731 (>50mg/g) ned in the TAG were C1610 (218 mg/g), C20:5 n-3 (167 mg/g) and C22:6 n—3 (430 mg/g).

PTA-10208 Sample #3 A sample of crude oil from the microorganism deposited under ATCC ion No. PTA-10208 (Sample PTA-10208 #3) was analyzed using HPLC/ELSD/MS. A total of 98.38% of lipids were recovered, with the sterol ester (SE) fraction accounting for 0.32%, the TAG fraction accounting for 96.13%, the 1,3-diacylglycerol (DAG) fraction fraction accounting for 0.22%, the 1,2-DAG fraction accounting for 0.78%, and the sterol accounting for 0.93%.

PTA-10212 Sample #1 The fatty acid proﬁle of the biomass and extracted crude lipid for PTA-10212 Sample #1 was determined using . Fatty acids in the biomass were transesteriﬁed of the in sizu by weighing 27.0 mg of biomass ly into a FAME tube, while a sample extracted crude lipid was prepared by weighing 52.5 mg of crude lipid into a 50 mL volumetric ﬂask and transferring 1 ml to a separate FAME tube. The estimated crude lipid content of the biomass was determined to be 38.3% (as SUM of FAME) using GC with FID detection, while 36.3% (wt/wt) lipid was extracted from the dry biomass, giving a 94.6% recovery of total lipid. The crude lipid was determined to be 83.2% fatty acids (as SUM of FAME) using GC/FID. The major fatty acids contained in the crude lipid were C1620 (328.5 mg/g), C20:5 n—3 (90.08 mg/g), and C22:6 n-3 (289.3 mg/g).

The lipid class proﬁle of the extracted crude lipid was determined by weighing into an 52.5 mg of crude lipid into a 50 mL volumetric ﬂask and erring an aliquot HPLC vial for HPLC/ELSD/MS analysis. According to the HPLC/ELSD/MS analysis, the crude lipid contained 0.2% SE, 64.2% TAG, 1.9% FFA, 2.8% 1,3-DAG, 1.4% sterols, 18.8% 1,2-DAG, and 0.5% MAG. 3.4% of the TAG fraction included a peak 'that eluted directly after the TAG peak,,but did not give a recognizable mass spectrum.

Isolated TAG from this sample made up approximately 49.8% of the crude oil.

Isolated PL made up approximately 8.1% of the crude oil. The major fatty acids (>50mg/g) contained in the TAG fraction are C1610 (400 mg/g), C20:5 n-3 (91 mg/g), and C22:6 n—3 (273 mg/g). The major fatty acids /g) contained in the PL fraction are Cl6:0 (98 mg/g), C20:5 n-3 (33 mg/g), and C22:6 n-3 (227 mgg).

PTA-10212 Sample #2 The fatty acid proﬁle of the biomass and extracted crude lipid PTA-10212 Sample #2 was determined using . Fatty acids in the biomass were transesteriﬁed in situ by weighing 29.5 mg of s directly into a FAME tube, while a sample of the ted crude lipid was prepared by weighing 56.5 mg of crude lipid into a 50 mL volumetric ﬂask and transferring 1 ml to a te FAME tubes The estimated crude lipid content of the biomass was determined to be 40.0% (as SUM of FAME) using GC with FID detection, while 413% (wt/wt) lipid was extracted from the dry biomass, giving acids a 106.1% ry of total lipid. The crude lipid was determined to be 82.8% fatty (as SUM of FAME) using . The major fatty acids contained in the crude lipid were Cl6:0 (327.3 mg/g), C2025 n-3 (92.5 mg/g), and C22:6 n-3 (277.6 mg/g).

The lipid class proﬁle of the extracted crude lipid was determined by weighing 56.5 mg of crude lipid into a50 mL volumetric ﬂask and transferring an aliquot into an HPLC vial for HPLC/ELSD/MS analysis. According to the HPLC/ELSD/MS analysis, the crude lipid contained 0.2% SE, 58.2% TAG, 2.3% FFA, 3.4% 1,3-DAG, 1.7% sterols, 23.4% 1,2-DAG, and 0.6% MAG. 3.3% of the TAG fraction included a peak that eluted directly aﬁer the TAG peak, but did not give a recognizable mass spectrum.

Isolated TAG from this sample made up approximately 51.9% of the crude oil.

Isolated PL made approximately 8.8% of the crude oil. The major fatty acids (>50mg/g) contained in the TAG fraction are Cl6:0 (402 mg/g), C2015 n-3 (92 mg/g), and C22:6 n—3 (245 mg/g). The major fatty acids /g) contained in the PL fraction are Cl6:0 (121 mg/g), C20':5‘n-3 (48 mg/g), and C22:6 n-3 (246 mg/g).

Table 4: Fatty Acid Proﬁles of PTA-10208 and PTA-10212 Biomasses and Extracted Crude Lipids (mg/g) PTA-10208 PTA-10208 PTA-10208 PTA-10208 PTA-10212 PTA-10212 PTA-10212 PTA-10212 9.39 'TA-10208 PTA-10208 PTA-10208 208 PTA-10212 PTA-10212 PTA-10212 PTA'10212 .37 8.96 . —m— . -0.00.3:- .00 m.00 1.79 1.85 —3.09 - .°8 mm 2 OO 2.28 .2 C22:0 0.10 0.08 0.30 _-0.12 .3 C20:4 11-7 0.81 ‘ 0.45 0.67 mm 12.23 6.84 12.18 —1l.3 IE.m 0.52 0.46 0.00 _0.00 _ m .45 333 5.58 0.00 2.40 m C20:3n-3 0.09 m 92.99 169.32 C24:0 0.52 , 1.55 3.26 0.85 2.04 . .84 10.27 17.98 9.92 17.50 2.41 246.98 423.10 245.96 444.08 139.58 -13735 Table 5: Fatty Acid Proﬁles of PTA-10208 and PTA-10212 Biomasses and Extracted Crude Lipids (%) —m m _m Im- —m m WO 13211 P-TA 10208 PTA:10208 PTA-10208 PT-A 10208 PTA— 10212 PT-A 10212 PTA-10212 PTA-10212 f Sample #1 Sample #1 Sample #2 Sample #2 Sample #1 Sample #1 Sample #2 Sample #2 Biomass Crude Li id Biomass Crude Liid Biomass rude Lisin Biomass Crude Liid C181n7 000 m C181—2n6 mm _o08 C20:0 — C182-3n3 C202-1n9 m C18:-4n3 — .21 0. 0‘N n6 m C20:-3n6 m C22:0 002 I!!- 0. Oon C20z-4n7 015 m—013 C20z-4n6 1.37 — .29 0.32 C22:—1n9 mm- C20z-4115 012 .m- C20z4n—3 0.65 m 0.59 064 C20:3n-3 m— C20.5n-3 2036 20.59 17.93 17.96 11.57 n9 mm m 0.76 _I111- C24z1n9 0.29 —m 0.22 0.12 — - C22:5n3 388 _lnl C-22.-6113 46.85 —6.64 47.42 47.10 37.94 -TA-10208 PTA10203 PTA-10208 PTA 10208 PTA 10212 PTA 10212 PTA10212 PTA10212 Sam-lei" Sam 1e#l Sam 16172 S. le#2 Sam leﬂl Sam-le#1 Samoleng Samle#2 E! :m c120 2.57 02— 3.35 0.36é 000 Z" —mmm-- —mmm mun-m- —m — ——— _m—m Imam-111! 10208 PTA-10208Sam 1le#l PTA- 10208 PTA l02l2 PIA-10212 PS’lA-l0212 PlA-lOZIZ Sample #2 Samlc#2 Samdeiil amle#l amlc#2 Sam le#2 —ml . - m m —mmm- .22 0.00 0.00 0.00 0.00 — m m m 0.00 —0 00 —m m. m C22:4n-9 m m 0.00 0.00 m W~ /\O .— m Table 7: Fatty Acid Proﬁles of PTA-10212 Isolated PL —PTA-10212 PTA- 10212 Sample #1 Sam-le#l Samle #2 Samle #2 % FAME 0.82 9-829 23.50 C18:0 3.25 0.78 <0. I 0.00 —-m- C2220 —10.12 44.7] 9.24 C2023 n-3 C20:4 n-6 0.84 0.20 .—54- C20:4 n-3 <0 I <0.1 0.27 C20 5 n-3 33 39 7.98 C2420 <0 1 <0.l 54.20 246.09 {It .0 00 (II mm— —-n- PTA-10212 Sample #3 The lipid content of the biomass for 212 Sample #3 was estimated to be 34% as the sum of FAME, and the amount of crude oil obtained after solvent extraction was 37% by weight, giving a 109% recovery of fat present in the biomass. Aﬁer - fractionation using ﬂash chromatography, imately 46% of the crude oil was isolated as TAG, 28% was isolated as DAG, The crude oil contained 309 mg/g DHA and 264 mg/g EPA. The isolated TAG contained 341 mg/g DHA and 274 mg/g EPA. The isolated DAG fraction contained 262 mg/g DHA and 237 mg/g EPA. The total fatty acid proﬁles of the biomass, extracted crude oil, and isolated fractions are shown below in Table 8 and Table 9 calculated as mg/g and % FAME, respectively.

Table 8: Fatty Acid Proﬁles of PTA-10212 Sample #3 Biomass and Extracted Crude Lipid (mg/g) —-——TAG FAME(mg/g) FAME (myg) FAME (mg/g) FAME (ngg) —mm--_-m ss Crude Oil 181.8 231.7 111.3 5905'Axl 10.2 14.2 pO :‘9‘ N\l _. 00 .ws: aw N . — — .— 7 \O' 9°.~' mu 263.6 274.2 237.4 .. \I b.) \D 00 Lo) 10.7 C22.Sn-3 15.1 C226n-3 131.2 309.4 3411 Sum of FAME 342.4 871. l 973.2 682.6 Table 9: Fatty Acid Proﬁles of PTA-10212 Sample #3 Biomass and Extracted Crude Lipid (%) 460% FAME (mg/g) mum No N N Crude Oil TAG CO . O\l 9.— 00M :- KI! 9.0 WM C2210 O N‘ O N. c . o N .o N ‘ _. N N C2024 n-3 C2015 n-3 29.8 30.3 -— N 38.3 35.5 DJ kl: I Total % FAME PTA-10212 Sample #4 PTA-10212 Sample #4 contained approximately 23% lipid determined as the sum of FAME, of which 107% was red using hexane extraction. Aﬂer fractionation using ﬂash chromatography, approximately 42% of the crude oil was ed as TAG, 18% was isolated as DAG. "The crude oil contained 275 mg/g DHA and 209 mg/g EPA.

The isolated TAG contained 296 mg/g DHA and 205 mg/g EPA. The ed DAG fraction contained 245 mg/g DHA and 219 mg/g EPA. The total fatty acid proﬁles of the biomass, extracted crude oil, and isolated fractions are shown below in Table 10 (mg/g) and Table 11 (%FAME).

Table 10: Fatty Acid Proﬁles of PTA-10212 Sample #4 Biomass and Extracted Crude Lipid (mg/g) -Biomass Crude Oil TAG DAG W1.% NA FAME C18:ln-7 0.0 .0 u .— N .C1823 n-3 4;... CA..

Table 11: Fatty Acid Proﬁles of PTA-10212 Sample #4 Biomass and ted Crude Lipid (%). 247% Fatty Acid 5'NAE (mg/g) warns/g) FAME _ 65 - —_Crude Oil O _-m- —-— N@Nq_ —— N N. _~m_ _" .o q _-m- 0 A. mu 0 N. —lm-m- n— . V. —-m- —-m— 26.5 Nw O uN O\ m- 0 I...) _.-m- —.__22.5n-6 C2225 n-3 Total % FAME PTA-10212 Sample #5 A sample of crude oil was extracted from a biomass of PTA-10212 using the FRIOLEX® s (GEA lia Separator UK Ltd., Milton Keynes, England) to yield microbial oil PTA-10212 Sample #5. Individual lipid classes were isolated from PTA-10212 Sample #5 using low pressure ﬂash chromatography, and the weight percent of each class was determined. The fatty acid proﬁle of each class was determined using GC-FID. {0200] Brieﬂy, the sample was prepared by dissolving 240 mg of crude oil in 600 uL of hexane and applying to the head of the column. After fractionation of the sample using 2012/047731 ﬂash chromatography, the. combined weights of all the fractions was 240 mg giving a . 100% recovery. The stem] ester fraction accounted for 0.9%, the TAG fraction accounted for 42.6%, the free fatty acid (FFA) fraction accounted for 1.3%, the sterol fraction accounted for 2.2%, the DAG fraction accounted for 41.6%. The total fatty acid proﬁles of the FRIOLEX® crude oil and isolated ons are shown below in Table 12 and Table 13 calculated as mg/g and % FAME, respectively.

Table 12: Fatty Acid Proﬁles of PTA-10212 Sample #5 Crude Oil (mg/g) "n 5mm) "-r- —-——3.8 —-m-m- ———-z- —--__0.7 C22 . 1 n-9 m- c2031 n-S _ C22:6 n-3 305.6 353.8 Sum of FAME 796.6 905.3 Table 13: Fatty Acid Proﬁles of PTA-10212 Sample #5 Crude Oil (%) EXAMPLE 4 The ve amount and fatty acid composition of each TAG isomer present in the extracted crude lipid was determined for each of samples PTA-10208 Sample #1,, PTA- 10208 Sample #2, PTA-10212 Sample #1, PTA-10212 Sample #2, and PTA-10212 Sample #3, 212 Sample #4, and PTA-10212 Sample #5 from Example 3 using non-aqueous reversed phase HPLC separation and APCI-MS detection.

TAG Method - Instrument ’ Agilent 1100 HPLC Agilent 1100 MSD Column(s‘) Two enex Luna C18 (2), 150 x 4.6 mm, 3 pm particle size connected in series Mobile Phase A — Acetonitrile B — IPA w/ 0.1% Ammonium Acetate Gradient _ Column Temp. 20°C Flow Rate 0.5 mL/min Injection Volume 5 uL MSD Mass Range 350 — 1150 Fragmentor 225 V Drying Gas Temperature 350°C, Vaporizor Temperature 325°C ary Voltage 3500 V Corona Current 10 pA PTA-10208 Sample #1 The crude lipid isolated from PTA-10208 Sample #1 was prepared for TAG is prepared for TAG analysis by weighing 5.5 mg of oil into an HPLC vial and diluting with 1 mL of hexane.

Table 14: Identiﬁcation ofTAG Species in PTA-10208 Sample #1 _-Retention . . l-MlArea .. . Major (DAG) EPEPA/EPA 945.8 962.7 643.5 A/DHA 971.7 988 8. 643.4, 669.5 DHA/Dl‘lA/EPA . _1014 7. 669.5, 695.5 ommm 32 mam Ill—-_ mm 999 8 . . 671.5, 697.5 DHA/EPA/ARA 973.8 990 7' 645.4, 671.5 . DHA/DHA/DPA 1025.7 1042 s 697.5 ownwm IE- 999.8 l016.8 671.5, 697.4 51 47 2 DHA/DPA/DHA _1.5 1025.7 1042 8. . 695.5, 697.5 —-———_m _-—————2.24 ———-——3.4 —-_———m . _2.3 -2.9 . mmwo Ill-_— —-—————2.0 —-—_-_—2.3 —-_——_m min-_—1.5 --_———m —-————_6.5 PTA-10208 Sample #2 The crude lipid isolated from PTA—10208 Sample #2 was prepared for TAG analysis ed for TAG analysis by weighing 5.3 mg of oil into an HPLC vial and diluting with 1 mL of hexane.

Table 15: Identiﬁcation ofTAG Species in PTA- .1. 0208 Sample #2 -_-— —n-—-—— b) O WWW n w WWW .2 l4) mwm s WWWﬂ"- 48.86 3N DHA/DHA/DPA 1025.7 1042 8 697.5 50.16 51.37 D) omwm II- 54.57 U) .o 55.78 u DHA/DHA/Mzo .9 w 3 | DJ6 Wm-——— 38 —n——_ 38 DHA/DPA/16:0 623.6, 625.4, 697.6 /1420 EPNARA/16:0 901.8 918.8 . 597.6,599.5,645.4 . (a) numcszom —_—— 44 an 18:0/16=0/DI-IA PTA-10212 Sample #1 The crude lipid isolated from PTA-10212 Sample #1 was prepared for TAG analysis prepared for TAG is by weighing 5.3 mg of oil into an HPLC vial and- diluting with 1 mL ofhexane.

Table 16: Identiﬁcation ofTAG Species in PTA-10212 Sample #1 Retention . . Area + + --————— so mm... —2.6 . . 45.41 30 DHA/DHA/DHA 2.4 DHA/EPA/14:0 ' 54 78 34 0.7 DHA/DHA/l6:1 - 949.7 966.7 621 3 695 3 59 53 Uh) 5 DHA/l5:0/DHA m 937.8 954 8 . 609 6 695 5» a :0/EPA -1.5 899.7 916 7. 597 5 643 2. > La) Ch EPA/16:0/DHA 3 , DJ O\ z0/DHA L») 00 DHN18=0/EPA _-—_1.5 UL» W90 DHNARNI6=°_-—_0.7DHA/DPNI6=0 -_-—0.7 . 3 00 DHA/DHA/l 8:0,_—_-0.7 . 4:O EPA/16:0/16:I _0.5 851.7 868.6 549 4 DHA/l8: 1/14:O IE- 877 7 894 7 549.5, 621.5, 623.3 bC) DHA/l6:0/14:O -1.7 851.8 868.8 523 S 623 5. , J} 1 EPA/1 5:0/16:0 I!- ., 78.59 DHA/l6:0/15:0 _2-5 _—, #54355 AUNN EPA/16:0/16:0 - ., DHA/I620/1620 —-—_ DHA/l720/16:0 DPA/l620/l620 III—_— J; DHA/16:0/l8:0 46 l6:0/16:O/16:l _——— 2012/047731 m:16 0/16:0/l4:0 Il- 779.7‘ 796.7 523.4, 551.3 m— 935.9 - 952.8 567.5, 607.6 _-—_——_ND D 936.8 551.5, 663.5 ND= Not Detected PTA-10212 Sample #2 The crude lipid isolated from PTA-10212 Sample #2 was prepared for TAG analysis prepared for TAG analysis by weighing 3.6 mg of oil into an HPLC vial and diluting with 1 mL of hexane.

Table 17; Identiﬁcation of TAG Species in PTA-10212 Sample #2 —-—-- ""NEW'4‘F’n"— DHA/DHA/16.l ND 966.7 62l.3 _-———mm —-———_m —---—_m --__——m —-——_-nmml --————m -——_——n WO 13211 16:0/1620/15:0 Ill—- 537.3, 551.5 m_—_ N 1009.0 663.5 N 880.9 551.3, 607.7 m. N 937.0 551.5, 663.5 ND= Not Detected PTA-10212 Sample #3 A sample of the TAG fraction of PTA-10212 Sample #3 was prepared in hexane and analyzed by HPLC/APCI/MS to determine the identities of individual TAG isomers.

Table 18: Identiﬁcation ofTAG Species in 212 Sample #3 Retention Identiﬁcation Area I eak #, 1M+H]’ M + NH4| * (DAG) Fragments T1me. Percent 7 _7 ‘ ' .016 — EPPA/EPA 3.7 945. 962.7 643 _‘ .471 EPA/EPA/DHA 971.6 988.7 643.5 6695 .970 DHA/DHA/EPA 6.5 997.7 1014.7 695.5 6695 . 21.441 n DHA7DHA/DHA 3.7 1023.7 1040.7 21.855 EPA/EPA/DPA 0.7 DHA/EPA/DPA 999.5 1016.7 22"" n EPA/EPA/ARA 947.5 964.6 643 3, 645 3 22.573 EPA/ARA/DHA 2.2 973-7 990-7 23.057 DHA/EPA/DPA 1.4 999.6 1016-7 . 1025.7 1042.7 695 5 697.5 23.548 DHA/1420/EPA 897.7 914.7 569.4 595.3 12 940.7 595.5 621 3 . 923.5 07 897.6 914.7 595 3 . _ 24.509 ._ 2 DHA/1621/DHA 949.6 966.7 621 3 24.783 1 b3 DHA/1410/DHA 0.5 923.7 940.8 595.5 .571 :0 IDHA 911.7 26.026 15 DHA/l 5 0/DHA 07. 937.7 26.376 EPA/16 O/EPA 72. 899.7 26.832 17 - EPA/16:0/Dl-1/i‘ 14.3 925.7 27.272 " DHA/1620/DHA 13.2 951.7 27.842 n DPA/1420/ARA 0.5 28.048 -20 EPA/18:0/EPA 927.6 944.7 623 4 28.271 DHA/1620/ARA 927.7 DPA/1621/DPA 953.7 28'5E N 'w ARA/16: l/ARA 901.8 918.6 5974 29.060 DHA/l6:0/ARA 2.6 927.7 29.381 DHA/l8:0/EPA ' 953.8 29.512 DHA/l6:0//DPA 953.8 .654 DHA/16:0/16:1 1.4 877.8 894.7 549.5 623.5 31.015 DHA/1620/14:0 8u: LI 868.7 523.3, 623.7 --—m865.8 882.7 5375,6233 853.5 - 870.7 551.5, 597.5 _-—m881.7 898.7 551.5, ND 907.8 579.4, 651.3 ND= Not Detected PTA-10212 Sample #4 {0207] A sample of the TAG fraction of PTA-10212 Sample #4 was prepared in hexane and analyzed by HPLC/APCI/MS to determine the identities of individual TAG isomers.

Table 19: ﬁcation of TAG Species in PTA-10212 Sample #4 -mRetention Identiﬁcation _M}Area ,. l IM + NH4] * (DAG) Fragments —2.3. mm-4.4 _971.6 9887. 6435,6695 mm... 4.7 997.7 1014 7 695 5 669 5' DHA/DHA/DHA 1023 7. 1040 7 695 5 21 6 =4.1 ' EPA/EPA/DPA 973 7 , 990.7 645.3 671 3 A/DPA 999.5 1016.7 697.5, 671 4 EPA/ EPA /ARA 947.5 964 6 645 3 —-——1.1 990.7 6715 6455. ll DHA/EPA/DPA -0.5 999.6 10167 696.5 6714 ﬂDHA/DPA/DHA _0.2 1025 8 1043 8 697 7 :1! DHA/l6zl/ DHA -0.3 949 6 966 7 _—IIIm923.5 - 595 4 -12 __———: 0 .4 —-—-m—_ —-———_lu IE EPA/lSIO/EPA —2.0 9216 - 2 .3 ARA/16:1/ARA 901.8 918.6 597 4 -L4 944 7. 599.3, 623 4 _1.5 953.8 970.3 625.4 651 5 -0.7 651 5 . 996.7 DHA/16:0/16:l 877.8 894.7 5495 N1) 825.6 842.6 549.5 ND —--——_m _-—-n: 865.8 882.7 537.5, 623.4 —-—-4.4 853.5 5515,5975 2 DHA/l60/I6:0: 879.7 5515,6235 3 20/16:0 _2.3 881.6 898.7 5515,6255 WO 13211 _-——893 8- 9107- 565.5, ND 881 7- 898.7 551.5, ND DPA/l6:O/.l6:0 881.7 898.7 551.5, 625.5 -3.4 824.8 551.5 l6:O/16:O/|80 852.8 5513,5795 m991.7 1008.8 623.3, 663.5 ND= Not Detected PTA-10212 Sample #5 A sample of the TAG fraction of PTA-10212 Sample #5 was prepared in hexane and analyzed by HPLC/APCI/MS to determine the identities of individual TAG isomers.

Table 20: Identiﬁcation of TAG Species in PTA-10212 Sample #5 .—----— 21.5 N A/DHA 5.5 971.6 22.0 A/EPA 7.6 997.7 22.5 DHA/DHA/DHA 4.5 1023.8 23.0 5 EPA/EPA/DPA 0.5 973.8 DHA/EPA/DPA 999.7 1016.7 697.5 671 5 23'3 1.5 131w EPA /ARA 947.6 964.8 645 5 EPNARNDHA n 973.6 990 7 671 5 645 4 23.7 DHA/DPA/DHA 1025.7 1042 7 695.5 697 5 24.2 DHA/EPA/DPA " 999.7 1016 7 669.5. 671.4 696 5 DHA/DHA/DPA 1025.7 1042 9 695.5 697 5 24.8 DHA/l4:0/EPA 897.7 914.7 595.5 .3 DHA/lézllEPA 0.7 923.8 940.8 595.5, 621.3 .6 DHA/1410/EPA 897.7 569.3, 595.4 .8 2 DHA/l6zl/ DHA 0.5 949.7 966.7 621 3 695 5 26.0 3 DHA/l6: l/EPA 923.7 940.8 595.5 621 3 26.9 EPA/15:0/DHA 0.7 911.7 5835 6093 27.4 l UI Dl'lA/lSZO/DHA 0.7 9376 27.8 EPA/16:0/EPA 4.9 899.7 28.2 28.7 DHN16IO/DllA 12 2 29.3 0.6 29.5 0 1.5 .0 1 3.4 .6 31.0 23 1.7 31.3 2h HA/l4:0 " 851.7 868.7 5955,6235 32.3 18:1/14:O/Dl-IA _1.7 877.7 8947 549.5 5955 28 Dl-lA/1610/l4:0 I11- 851.8 868.7 523.4 623.5 2012/047731 EPA/15:0/l6:0 839.7 856.7 5375,5333 335~ 29 DHA/20:0/EPA 981.7 998.8 653.5, 679.6 865 7- 882.7 537.5. 623.5 ammo/16:0 853.8 870.7 551.5, 597.5 .2 32 DHA/16 0/1620 36.4 33 DPA/16:O/l6:0 881.7 898.7 551.5, 625.5 —-—m907.7 924.7 579.4 1037.8 1054.8 709.5, 735.6 In ' 1064.8 1081.8 735.7 EXAMPLE 5 Crude oils were further sed via reﬁning, bleaching, and deodorizing to obtain reﬁned oils. The reﬁned oils were diluted with high oleic sunﬂower oil to obtain ﬁnal oils with a DHA t of approximately 400 mg/g. Individual lipid classes were isolated and the fatty acid proﬁles of each class was determined using GC—FlD as FAME.

PTA-10208 Final Oils The fatty acid proﬁles for PTA-10208 Final Oils #1-5 are summarized in Tables 21-22, including proﬁles associated within the isolated TAG on (Tables 23-24) and the isolated sterols/DAG fraction (Tables .

Individual lipid classes in the ﬁnal oils were also determined using ﬂash chromatography (Table 27) and normal HPLC with ELSD and APCI-MS conﬁrmation (Table 28).

Table 21: Fatty Acid Proﬁles of PTA-10208 Final Oils (mg/g) -PTA—10208 PTA-10208 PTA-10208 PTA-10208 PTA-10208 Final 01m. Final on #2 Final on #3 Final 011 #4 FinalOil#5 FAME (mg/g) FAME(mg/g) FAME (mg/g) Fm": is"? N (II w. 00 Os4?- ‘3’ \l C2025 n 3 173.8 C22 4 \n-9 C24:1 n-9 W .5 C22z5 n-3 43.9 C22:6 11-3 394.8 Sum ofFAME 918.1 ; PTA-10208 PTA-10208 208 PTA-10208 Final Oi|#l Final Oil#2 Final Oil#3 Final on #4 Final Oil #5 mm we O b) 0—0 0 - __-E- 2 C1411 0.0 . CONN m I!- os "— I19.2 .1 . o. _-m-—- 0 ._.

O\ co.-2co 2 A _ .l Cl8z2n-6 04 . u. 0.4 Ao _.

C b) O U _—-7 0.2 00 MN 9N o N. _—-6 L4 1.3 .— ll: _- M. —-a--9 C20z4 \n 5- —0.2 0.2 O N C20:4 \n 3- —0.7 .o \l 0L: 17.5 21.5 22.7 C24 0 m- D N _m-9 0.3 9N O . b) --m-6 —-x_-3 4.4 PA -3 40 8‘ 40.5 Table 23: ed TAG Fatty Acid Proﬁles: PTA-10208 Final Oils (mg/g) Final Oil #1 Final Oil #2 Final Oil #3 Final Oil #4 Final Oil #5 "__mm- —._mm-m-m "mm-Im- _mI-"_— "ml-mum- —m_m-m_-m-m _-—_—m- "mm-".m- mum-n "In-m".- _Mm-m- —m-__—m- C2025 n-3 176.0 Table 24: Isolated TAG Fatty Acid Proﬁles: PTA-10208 Final Oils (%) PTA-10208 PTA-10208 PTA-10208 PTA-10208 PTA-10208 Final Oil#1 Final Oil#2 Final Oil#3 FinalOil#4 Final Oil #5 Fatty Acid % FAME % FAME % FAME % FAME % FAME 0-3 03 ___—m0.3 _-m-m ___— ___—_m- "mu-mm- "um-_—- 2 C181n'-7= _=__-<0.1 0.3 0-4 0-4 C2020 0 0-4 0-4 C183 n-3' 0.0 0.0 ‘1- C20.l n 9' 111 O IO 0-3 0.3 ___" ___" 0-0 0-0 .m- I!- 02024 n-6 1.4 1 5 0.0 .mm. mu _7 - —-E_ 17 6 21 5 22 7 0.1 .1- C2224 n 9- m C241] n-9 0.4 .o w O N C22:5 n-6 L Table 25: Isolated Sterols/DAG Fatty Acid Proﬁles: PTA-10208 Final Oils (mg/g) Final Oil#l FinalOil#Z FinalOil #3 Final Oil #4 Final Oil#5 FAME (mg/g) FAME (mg/g) ___-___ _mn—"m —m_-m-m_-m--m- 01820 ___-i." Clszln—9 ___—m ___—"l- awn-6 C20:0 ___-I." cum n-3 mum-"mm- <0.1 <01 moan-6 "mum-m. 020:3n-6 ._ <0.1 ___-mm" _munx-"m-m ___-n— _lmmm-"m- ___—"- ___—"- ___-___ _mmmum-m- ___—___ Table 26: Isolated Sterols/DAG Fatty Acid Proﬁles: PTA-10208 Final Oils (%) ___-_-FinalOil#1FinalOil#2 FinalOil#3 FinalOil#4 FinalOil#5 _—0.3 ___-mm" —m_-m--m-m-m_ ___——m- ___—M <0.1—_" --m-m_m--_ __m-m "ml —-m_m--m- —-m- —-m- —-m- Table 27: Lipid class separation by ﬂash chromatography (wt %) l#1 FmalOll#2 Final Oil #3 Fmal Oil #4 Final Oil #5 93-4 ___-m:0 Table 28: Lipid class separation by HPLC-ELSD (wt %) PTA-10208 Final Oil #5 0 .3 Final Oil #6 0 36 ND: Not Detected PTA-10212 Final Oil DHA was present in a PTA—10212 Final Oil at 41.63% and 366.9 mg/g, while EPA was present at 16.52%. Individual fatty acid proﬁles were determined and are summarized in Table 29.

Table 29: Fatty Acid s of.PTA-l0212 Final Oil (% FAME) -—ND —_ND —_ND : —ND CH 0 €12 0 —ND C13 0 -ND €141 —ND 0150 _.l_ WO 13211 awn-s czozln-g man-e C24:0 C24:1 n-9 ND= Not Detected EXAMPLE 6 An analysis of the triacylglycerides (TAGS) of the PTA-10208 ﬁnal oils in Example 5 was performed using techniques described in Example 4. The identiﬁcation of each fatty acid moiety was made, as summarized in Table 30’ below.

Table 30: Identiﬁcation of TAG Species in PTA-10208 Final Oil PTA-10208 PTA-10208. PTA-10208'PTA-10208 PTA-1020a Ide""°a'°"a. t.

Final omw FinalOil#2 Final on #3 Final on #4 FinalOil#5 Aea% Are % rea" . 7 DHA/EPA/ARA DHA/DPA/DHA DHA/1620/DHA DHA/l6:O/ARA 1.6 DHA/1620/DPA 1.3 DHA/18:0/DHA DHA/l4:0/l6:0 EPA/l6:0/l6:0 DHA/l 6:0/16:0 18:0/l6:0/DHA l8:l/l8:l/18l EXAMPLE 7 A two-day old inoculum ﬂask of the isolated microorganisms deposited under ATCC Accession Nos. PTA-10208 and 10212 was prepared as a carbon and nitrogen-fed culture in media according to Tables 1 and 2.

Mutagenesis was carried out according to following procedure: A e T=2 day old ﬂask, approximately 50 ml, was poured into a sterile 40 ml glass homogenizer. The culture received 50 plunges in the homogenizer. The culture was pipeted out and ﬁltered through a sterile 50 micron mesh ﬁlter, which was placed‘in a . 50 ml sterile tube (the mesh was used as a means of retaining the larger clumps of colonies while letting the r clusters and single cells pass through the 50 micron . The entire concentrated macerate was collected in a sterile 50 m1 tube. The macerated culture was vortexed and dilutions at'levels up to 1:100 fold were made. The diluted macerate samples were vortexed prior to adding 200 pl of inoculum to a media Each plate was agar plate, 100 x 15 mm, containing 4-5 glass beads (3 mm glass beads). gently agitated in an effort to have the beads spread the inoculum evenly around the plate.

Beads were dumped off of plates and plates were leﬁ to sit with covers on for imately 5 minutes to dry. Lights in both the sterile hood and adjoining areas were turned off as the procedure was performed in dim light. There was minimal light available to be able to run the procedure but only indirect and dim.

Five replicate plates were placed on the ﬂoor of the XL crosslinker (Spectronics Corporation, New York) with the lids off while the s were irradiated. The crosslinker red power in terms of microjoules and a level was sought that achieved a 90%-95% Kill. Five ate control plates were ated with un-mutagenized cells using the same protocol. These cell counts were used to calculate the % Kill. Once the WO 13211 irradiation was ﬁnished the plates were taken out, the lids were replaced, and the plates were wrapped in paraﬁlm followed by a wrap in aluminum foil. ~_It was imperative that the plates grew for the ﬁrst week in ~the dark so that they were not able to repair the damaged genes.

Plates were placed in a 22.5°C room for about 10 days prior to counting the colonies. When ﬁnal counts were made, dual colonies were picked with a sterile inoculating loop and re-streaked on new media plates. Each colony was plated on an individual plate. As plates grew dense a sample was taken, using a ating loop, and inoculated into a sterile 250 m1 shake ﬂask containing 50 ml of media. This ﬂask was placed on a shaker at 200 rpm in a 225°C room. On T=7 days the shake ﬂask culture was harvested into a 50 ml sterile tube. The pH was taken and the sample was centrifuged to collect the biomass . Each sample was rinsed and re-suspended in. a 50:50 mixture of isopropyl alcohol and distilled water prior to being re--centrifuged The collected pellet Was freeze dried, weighed, and a FAME analysis was med The dataIn Tables 31 and 32 represents mutants produced with the aboVe process from strains "PTA-10208 and PTA-10212, respectively.

Table 31: PTA-10208 Mutants control Mutant l Mutant 2 - Fa Acids PTA- 10208 PTA- 10209 P-TA10210 PTA- 10211 %08:0 0.00 0.00 %09:0 %10:0 %1120 % 11:1 %12:0 %12:1 %1320 %l3:l %l4:0 %l4:l m %15:l 2.66 222 176 m %160 24.87 24.97 2371 25.01 ‘_ %161 020 0.25 0.00 000 mm _%‘63m1. -— min-.m- FattyAcids PTA-10208 PTA-10209 PTA-10210 PTA-102]] %18:0——-M--E- _mmm-m- —-m--m--m--m- %18:3n-6 "M" "mm-m- —mm_-m_-m-m- _-_-m-ma_ 0.00 m—m % 20:3 n-9 0.00 _—-m_ % 20:3n-6 _-——m_ _W-m- — 0.11 "_- %22:3 "mm-mum- % 22:4n-6 Inn-mumm- —m_-m_m--m_ _mm-mumm Control Mutant 1 Mutant 2 Mutant 3 Fatt Acids PTA-10212 PTA-1 02 1 3 PTA-10214 PTA-10215 —-m--m_ % 11:0 000 m .0oo 0.21 O . \l \l 0.62 Fatty Acids PTA—10212 PTA-10213 PTA-10214 PTA-10215 —-m--m_-m--m- _-m--m_mm--m_ —-m--m-ma_-m- _m_m_-m_-m_ 0-27 _mm--m_m_mm ————m _nm_-m_-m--m_ —-m_-m__— _mt_-m_mm_-m- —-m_-m_-m_-m_ _-om-mm_-m-m- "mm-mm _nm-mz_mm_-m- --m_-m_ —-m_mm-mm_m_ _nm_-m_-m--m_ —-M_ 0.00 0.00 IE. "mum-m- —nm--m_-m-m_ % 22:6 n-3 DHA —-m_-m-mm_nm_ -m_mm--m--m_ 1.27 EXAMPLE 8 An oil was prepared according to the method described in Example 5 n the oil was diluted with high oleic sunﬂower oil to achieve a combined DHA + EPA content of at least about 500 mg/g oil. A typical analysis and product cation of an oil made according to this Example is set forth in Table 33. _ 87 - Table 33 _I—I§m_ DHA + EPA Content m/ oil fa Acids % Other ingredients contained in the oil include less than 2% of er Lecithin; Rosemary Extract; Tocopherols and Ascorbyl Palmitate (as antioxidants).

An oil Was prepared according to the method described in Example 5 wherein the oil was diluted with high oleic sunﬂower oil to- achieve a combined DHA + EPA content of at least about 400 mg/g oil. A typical analysis and product speciﬁcation of an oil made according to this Example is set forth in Table 34.

Table 34 DHA Content m ; oil Min. 240 Min. 120 — Min. 400 3333::$2322%? . Free Fat Acid% . owm MOO Ln.. ax. 0.02 ax. 4-5 Trans-fa Acids % ~ ELEMENTAL COMPOSITION MAX 0-1 MAX 0-1 <0-1 MAX 0-05 MAX 0-2 _ Lead 0 pm MAX 0-1 Mercury__ppm MAX 0-04 Other ingredients contained in the oil include less than 2% of Sunﬂower in; Rosemary Extract; erols and Ascorbyl Palmitate (as antioxidants).

In some embodiments, Examples 8 or 9 above are provided in a size 20 vegetarian gel e in a ﬁll weight of about 999 mg to about 1105 mg oil with the gross weight of the capsule being about 1463 mg to about 1789 mg wherein the capsule has a rupture time of not more than 15 minutes and has a shelf life of about 24 months.

All of the various aspects, embodiments, and options described herein can be combined in any and all variations.

Claims

The claims defining the invention are as follows:

1. A refined microbial oil comprising omega-3 polyunsaturated fatty acids comprising docosahexaenoic acid and eicosapentaenoic acid in an amount of >90%, by weight, of the total amount of omega-3 polyunsaturated fatty acids, wherein the amount of eicosapentaenoic acid, by weight, is from 29% to 55% of the total amount of docosahexaenoic acid and eicosapentaenoic acid, and the amount of docosahexaenoic acid, by weight, is from 45% to 71% of the total amount of docosahexaenoic acid and eicosapentaenoic acid.

2. The oil of claim 1, wherein the oil comprises a triacylglycerol fraction of at least 35% by weight.

3. The oil of claim 1 or claim 2, wherein the amount of eicosapentaenoic acid, by weight, is from 29% to 43% of the total amount of docosahexaenoic acid and eicosapentaenoic acid, and the amount of docosahexaenoic acid, by weight, is from 57% to 71% of the total amount of docosahexaenoic acid and eicosapentaenoic acid.

4. The oil of claim 1 or claim 2, wherein the amount of eicosapentaenoic acid, by weight, is from 29% to 54% of the total amount of docosahexaenoic acid and eicosapentaenoic acid, and the amount of docosahexaenoic acid, by weight, is from 46% to 71% of the total amount of docosahexaenoic acid and pentaenoic acid.

5. The oil of claim 1 or claim 2, n the amount of pentaenoic acid, by , is from 29% to 38% of the total amount of docosahexaenoic acid and eicosapentaenoic acid, and the amount of docosahexaenoic acid, by weight, is from 62% to 71% of the total amount of docosahexaenoic acid and eicosapentaenoic acid.

6. The oil of claim 1 or claim 2, wherein the amount of pentaenoic acid, by , is from 29% to 46% of the total amount of docosahexaenoic acid and eicosapentaenoic acid, and the amount of docosahexaenoic acid, by weight, is from 54% to 71% of the total amount of docosahexaenoic acid and eicosapentaenoic acid.

7. The oil of any one of claims 1-6, wherein said oil ses 120 mg to 220 mg eicosapentaenoic acid per one gram of oil and from 240 mg to 450 mg docosahexaenoic acid per one gram of oil.

8. The oil of any one of claims 1-6, n said oil comprises from 130 mg to 195 mg eicosapentaenoic acid per one gram of oil and from 320 mg to 480 mg docosahexaenoic acid per one gram of oil.

9. The oil of any one of claims 1-6, wherein the omega-3 polyunsaturated fatty acids further comprise pentaenoic acid in an amount of from 0% to 10%, by weight, of the total amount of omega-3 polyunsaturated fatty acids.

10. The oil of claim 9, wherein said oil comprises 150mg to 300 mg eicosapentaenoic acid per one gram of oil; from 200 mg to 400 mg docosahexaenoic acid per one gram of oil; and from 0 to 55 mg docosapentaenoic acid per one gram of oil.

11. The oil of any one of claims 1-10, wherein said oil is produced by Schizochytrium sp.

12. The oil of any one of claims 1-11, wherein said oil comprises less than 5% by weight of each of arachidonic acid, docosapentaenoic acid n-6, oleic acid, linoleic acid, linolenic acid, eicosenoic acid, erucic acid and stearidonic acid.

13. The oil of any one of claims 1-12, n said oil comprises a triacylglycerol fraction of at least 10% by weight, wherein at least 12% by weight of the fatty acids in the triacylglycerol fraction is eicosapentaenoic acid, n at least 25% by weight of the fatty acids in the triacylglycerol fraction is docosahexaenoic acid and wherein less than 5% by weight of the fatty acids in the triacylglycerol fraction is donic acid.

14. A refined microbial oil comprising omega-3 polyunsaturated fatty acids comprising docosahexaenoic acid and eicosapentaenoic acid in an amount of >90%, by weight, of the total amount of omega-3 polyunsaturated fatty acids; and docosapentaenoic acid in an amount of from 0% to 2%, by weight, of the total amount of omega-3 polyunsaturated fatty acids, wherein the amount of eicosapentaenoic acid, by weight, is from 10% to 25% of the total amount of docosahexaenoic acid and eicosapentaenoic acid, the amount of docosahexaenoic acid, by weight, is from 75% to 90% of the total amount of docosahexaenoic acid and eicosapentaenoic acid.

15. The oil of claim 14, wherein the oil comprises a triacylglycerol fraction of at least 35% by weight.

16. The oil of claim 15, wherein said oil comprises from 55 mg to 150 mg eicosapentaenoic acid per one gram of oil; from 410 mg to 540 mg docosahexaenoic acid per one gram of oil; and from 0 to 12 mg docosapentaenoic acid per one gram of oil.

17. The oil of any one of claims 1-7 and 9-14, n the total amount of omega-3 polyunsaturated fatty acids is at least 400 mg per one gram of oil.

18. The oil of any one of claims 1-7 and 9-14, wherein the total amount of docosahexaenoic acid and pentaenoic acid is 400 mg per one gram of oil.

19. The oil of any one of claims 1-16, wherein the total amount of omega-3 polyunsaturated fatty acids is from 400 mg to 750 mg per one gram of oil.

20. The oil of any one of claims 1-16, wherein the total amount of omega-3 polyunsaturated fatty acids is at least 500 mg per one gram of oil.

21. The oil of any one of claims 1-16, wherein the total amount of docosahexaenoic acid and eicosapentaenoic acid is 500 mg per one gram of oil.

22. The oil of any one of claims 1-21, wherein said oil ses a ratio of EPA:DHA selected from 1:1 to 1:1.5, 1:1 to 1:2, 1:1.5 to 1:2, 1:1 to 1:2.5, 1:2 to 1:2.5, and 1:4 to 1:7 by weight of total omega-3 polyunsaturated fatty acids.

23. An oral dosage form comprising the oil of any one of claims 1-22.

24. The oil of claim 1 or claim 15, substantially as before described, with reference to the Examples. 2715270PC01SequenceListingasciitxt.TXT